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ABSTRACT 
 
Zara Ahmed: CDC Engagement with the Global Fund: Current Approaches and Opportunities for 
Enhanced Collaboration 
(Under the direction of Sandra Greene) 
 
 
The U.S. Centers for Disease Control and Prevention (CDC) is one of the U.S. government’s 
(USG) largest public health agencies and leading implementers of global health programs. Primarily a 
domestic agency, CDC has expanded its global health work dramatically over the last 15 years via the 
President’s Emergency Plan for AIDS Relief (PEPFAR), the President’s Malaria Initiative (PMI), and 
global tuberculosis control efforts, as well as through the Global Health Security Agenda and 
international Ebola response. To maximize the use of these resources and leverage funding from other 
partners, CDC has sought to increase collaboration with the Global Fund to Fight AIDS, TB, and Malaria 
(GF). Created in 2002, GF is a multilateral partnership that raises money from governments, the private 
sector, and civil society to combat these three major infectious diseases. Together, the USG (including 
CDC) and GF control 27% of all global health funds, over $9 billion annually, and jointly work in 63 
countries. Given the significant funding being invested by both entities, maximizing programmatic and 
financial synergy is imperative for sustaining the public health gains supported by these organizations. 
However, little is currently understood about how CDC staff engage with GF and opportunities for 
improvement. 
The primary, overarching research question of this study was how can CDC improve 
collaboration with GF at headquarters and country levels in order to increase the impact of health 
investments by both entities. This analysis utilized both quantitative and qualitative data collected from 
CDC staff in two stages to broadly assess current CDC engagement with GF at various levels. The study 
found that there is a high degree of interest among CDC staff in GF and that engagement with GF is 
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considered very important to their work, but that they were not necessarily maximally effective in their 
collaboration. CDC staff face multiple challenges regarding GF, including low levels of self-reported 
knowledge, lack of training, unclear support and communication systems, and deficiency in dedicated 
staff or time for engagement. There is a desire for more strategic direction, training, and prioritization of 
GF collaboration, particularly among country-based staff.  
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CHAPTER 1: INTRODUCTION 
The U.S. Centers for Disease Control and Prevention (CDC) is one of the U.S. government’s 
largest public health agencies and leading implementers of global health programs.1 Primarily a domestic 
agency, CDC has expanded its global health work dramatically over the last 15 years. With the creation of 
the President’s Emergency Plan for AIDS Relief (PEPFAR) and the President’s Malaria Initiative (PMI) 
in 2003 and 2005 respectively, and subsequent establishment of new CDC offices in dozens of countries, 
CDC has dramatically expanded its footprint and role in global public health. Along with the U.S. Agency 
for International Development (USAID), CDC is charged with the implementation of these initiatives, as 
well as U.S. Government (USG) global tuberculosis control efforts, known as TB Care 1.0 and 2.0. 
Further expansion of CDC’s global reach has been achieved through the Global Health Security Agenda 
and the international Ebola response.  
In order to maximize the use of these resources and leverage funding from other partners, CDC 
has sought to increase collaboration with major global health players, including UN agencies, 
foundations, other bilateral donors, and multilateral organizations. Chief among these has been the Global 
Fund to Fight AIDS, TB, and Malaria (GF). Created in 2002, GF is a multilateral partnership organization 
that raises money from governments, the private sector, and civil society to combat these three major 
infectious diseases.2 GF is primarily a financing institution and does not implement programs on the 
ground in developing countries, but rather relies on local governments and non-governmental partners to 
do so. A Country Coordinating Mechanism (CCM) is constituted in-country to serve as a forum for 
reviewing and monitoring GF grants, with membership from various sectors and a diversity of actors 
                                                          
1U.S. Centers for Disease Control and Prevention, Global Health Strategy, 2012—2015. Accessed February 11, 
2018. https://www.cdc.gov/globalhealth/strategy/pdf/CDC-GlobalHealthStrategy.pdf. 
2The Global Fund, Overview. Accessed February 11, 2018. https://www.theglobalfund.org/en/overview/ 
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(e.g., host government, other donors, civil society). Funding applications from the country, known as 
Concept Notes (CN), come through the CCM to GF headquarters (HQ) in Geneva, where they are 
reviewed by the Technical Review Panel (TRP), an independent committee of experts. GF allocates 
approximately 50% of global funding to HIV/AIDS, 32% to malaria, and 18% to TB; funding limits are 
set for countries based on disease burden, income status, and other factors.3 Once the grant is made, it is 
overseen by the CCM, an external auditing firm in-country (known as the Local Fund Agent [LFA]), and 
a dedicated team from GF HQ (known as the Fund Portfolio Management Team [FPMT]). The overall 
operations and strategy of GF is set by its Board. The U.S. Government is represented on the GF Board 
by the U.S. Global AIDS Coordinator (for the U.S. Department of State) and the U.S. Assistant Secretary 
for Global Affairs (for the U.S. Department of Health and Human Services). The USG is also the largest 
contributor to GF, annually comprising up to one-third of all funding provided to the financing facility.4 
Table 1 summarizes funding by both entities for the three diseases.  
Table 1: GF and USG Funding in Millions (2017)5 
Source HIV TB Malaria Total 
GF (Disbursement) $1,524 $731 $1,335 $3,590 
USG (Budget) $5,210 $191  $723 $6,124 
Total $6,734 $922 $2,058 $9,714 
 
                                                          
3The Global Fund, Detailed Explanation of the Allocation Methodology 2017—2019. Accessed February 11, 2018. 
https://www.theglobalfund.org/media/5642/fundingmodel_allocations2017-2019detailedexplanation_report_en.pdf 
4The Global Fund, Financials. Accessed February 11, 2018. https://www.theglobalfund.org/en/financials/. 
5The Global Fund, Portfolio Overview. Accessed April 28, 2017. http://portfolio.theglobalfund.org/en/Home/Index 
U.S. President’s Emergency Plan for AIDS Relief, PEPFAR Funding. Accessed April 28, 2017. 
https://www.pepfar.gov/documents/organization/252516.pdf  
U.S. Centers for Disease Control and Prevention, FY15 Operating Plan. Accessed 28, 2017. 
https://www.cdc.gov/budget/fy2015/operating-plans.html  
The U.S. President’s Malaria Initiative, About Us. Accessed April 28, 2017. http://www.pmi.gov/about 
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According to analysis by the Institute for Health Metrics and Evaluation, the USG is the second 
largest channel of all global health funding, after NGOs and foundations, and GF is the fourth largest; 
together, the USG and GF control 27% of all global health dollars (IHME, 2015), over $9 billion annually 
(Table 1).6 The USG and GF both share a focus on three infectious diseases: HIV, TB, and malaria, with 
over 91% of USG and 98% of GF resources being directed towards those epidemics.  
There is also significant overlap in geographic focus, with 63 countries around the world 
currently receiving support from both GF and USG, and 130 receiving support from either (Table 2).  
Table 2: Number of Countries Receiving GF and/or USG Support7 
Category HIV TB* Malaria Any Program 
Both GF and USG 56 15 24 63 
GF only 61 96 51 60 
USG only 9 1 1 7 
Total  126 112 76 130 
*USG TB countries are defined as those listed for CDC support on the CDC Global TB website. Eight of 
these countries are also priority countries for TB Care 2.0.  
 
After initial rapid scale up, funding for both GF and USG global health work has remained 
relatively flat since 2010 (Figure 1). However, the number of people in need of treatment for HIV 
continues to increase (Figure 2), and continued efforts are needed to sustain gains made in the fight 
against TB (Figure 3) and malaria (Figure 4). Continuing to provide needed services in an environment 
                                                          
6Institute for Health Metrics and Evaluation, Financing Global Health. Accessed February 11, 2018. 
http://www.healthdata.org/data-visualization/financing-global-health. 
7The Global Fund, Funding Allocation Model. Accessed April 28, 2017. 
http://www.theglobalfund.org/en/fundingmodel/allocationprocess/ 
U.S. President’s Emergency Plan for AIDS Relief, Bilateral Countries. Accessed April 28, 2017. 
http://www.pepfar.gov/countries/bilateral/index.htm 
U.S. Centers for Disease Control and Prevention, Global TB Program. Accessed 28, 2017. 
http://www.cdc.gov/tb/topic/globaltb/work.htm 
The U.S. President’s Malaria Initiative, Where We Work. Accessed April 28, 2017. http://www.pmi.gov/where-we-
work 
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with stagnant funding will require increased attention to efficiency and cost control by all actors, 
including GF and CDC.  
Figure 1: Global Fund and USG Global Health Resources, 2006—20178 
 
Figure 2: People Living with HIV Worldwide, 1990-20159 
 
                                                          
8Kasier Family Foundation, U.S. Global Health Budget Tracker. Accessed February 11, 2018. 
https://www.kff.org/interactive/budget-tracker/landing/ 
The Global Fund, Financials. Accessed February 11, 2018. https://www.theglobalfund.org/en/financials/ 
9 UNAIDS, AIDSInfo Tool. Accessed February 11, 2018. http://aidsinfo.unaids.org/ 
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Figure 3: Global Trends in TB, 1990-201510 
 
Figure 4: Global Trends in Malaria Cases, 2000-201511 
 
                                                          
10 World Health Organization, Global Trends in TB. Accessed February 11, 2018. 
http://www.who.int/gho/tb/epidemic/tb_001.jpg?ua=1 
11World Health Organization, Malaria World Report. Accessed April 28, 2017. 
http://www.who.int/malaria/media/world-malaria-report-2015/en/ 
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Given the significant funding being invested by both entities, as well as the epidemiologic 
demand, maximizing programmatic and financial synergy is imperative for sustaining the public health 
gains realized by these organizations. To this end, CDC has encouraged greater engagement by CDC HQ 
and field staff in GF processes and decision-making at various levels, with the hope of promoting more 
evidence-based and strategic choices. CDC staff routinely participate in various aspects of strategic and 
technical planning, budgeting, implementation, monitoring, and impact evaluation of activities supported 
by GF. Certain successes, challenges, and opportunities regarding CDC—Global Fund collaboration may 
be common across countries and disease areas, but have not been systematically documented and 
disseminated. This potentially hinders CDC encouragement of GF policy reform or improvements to 
technical approaches at the country level. Although efforts have been made to improve CDC 
contributions to GF processes over the past decade, CDC’s engagement—at both the HQ and field 
levels—is often developed and implemented in an ad hoc manner, resulting in less than maximally 
effective strategic direction and impact of GF resources. CDC has an opportunity to improve coordination 
of its overall engagement with GF, as the CDC brings significant global health expertise and field 
experience in GF’s three disease areas. The goal of this study is to examine current engagement by CDC 
with GF and to detail strategies for improvement. The overarching research question of this study is: How 
can CDC improve collaboration with the Global Fund at HQ and country levels in order to increase the 
impact of health investments by both entities? 
DEFINITIONS 
 GF and CDC have unique systems, processes, and jargon, which can make understanding their 
relationship challenging. On the GF side, key terms include “New Funding Model” (NFM), which is the 
method employed for resource allocation by disease and country adopted for the 2014-2016 period. 
“Concept Note” (CN) is the grant application under the NFM, and “Country Coordinating Mechanism” 
(CCM) is the in-country oversight mechanism, usually comprised of representatives from government, 
other donors, civil society, implementing partners, and affected populations’ representatives. “Fund 
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Portfolio Management Team” (FPMT) refers to the individuals from GF HQ in Geneva who oversee the 
portfolio and monitor performance.  
 On the USG side, CDC receives money from Congress through several multi-agency funding 
streams, including PEFPAR and PMI, as well as agency-specific appropriations for particular global 
health efforts. While CDC has some discretion over the distribution of funds between programs, many 
decisions are made by the Department of State. As such, CDC must work through the annual vertical 
planning processes for PEPFAR and PMI, known as the “Country Operational Plan” (COP) and “Malaria 
Operational Plan” (MOP) respectively, to shape the technical investments for a given country. There are a 
number of units within CDC involved in collaboration with GF, most notably the Center for Global 
Health (CGH) and its Division of Global HIV/AIDS and TB (DGHT) and Division of Parasitic Diseases 
and Malaria (DPDM).  
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CHAPTER 2: LITERATURE REVIEW 
I conducted a literature review to answer the following research question: 
What is the relationship between CDC and the Global Fund and how do the organizations engage with 
each other?  
METHODS 
I identified articles through iterative, systematic searches of major public health databases and 
scans of reference lists. The databases I reviewed included PubMed, PubMed Central, Scopus, Global 
Health, and Google Scholar. Reports from the Congressional Research Service were also searched. My 
search strategy employed the terms in the table below. 
Figure 5: Literature Review Search Terms (Major and Replacement) 
Major Terms Global Fund AND CDC 
Replacement Terms 
GFATM 
GF 
Global Fund to Fight AIDS, TB, 
and Malaria 
 
PEPFAR 
PMI 
TB Care 
US Government 
USG 
 
Eligibility Criteria 
Criteria for study inclusion were i) mention of GF and CDC (or one of the replacement terms 
above); ii) focus on, or discussion of, the relationship or interaction between the two; and iii) accurate 
initial description of GF and USG/CDC. Studies were excluded if they i) were about the technical work 
done by the organizations individually; ii) focused solely on their impact on civil society or other groups; 
iii) did not significantly discuss both organizations (i.e., only had passing mention of the other); or iv) did 
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not discuss the interaction between the organizations. I considered including articles from outside the U.S. 
if they met the other criteria. Selected articles were English-language and either appeared in peer-
reviewed publications or were prepared by well-established research organizations; blog posts, newspaper 
articles, and public fact sheets were excluded. The timeframe for this search was from 2002 to 2015, 
inclusive, given the establishment of GF in 2002.  
RESULTS 
Study Review and Selection 
 Once duplicate sources were removed, I reviewed titles and abstracts to assess potential relevance 
based on inclusion and exclusion criteria. In cases where it was unclear if the article fit the criteria, items 
were included and the full article retrieved. Of the 73 articles originally identified during the searches, 48 
were excluded based on title and/or abstract (Figure 6). The remaining 25 articles were accessed and 
screened, 18 were excluded based upon the review of the full text, and two additional pieces excluded 
during the data review process. A scan of the bibliographies of the full text articles (snowballing) was 
done to identify any other potential items for inclusion but none were deemed relevant. A total of five 
articles were thus considered relevant and included in the review.  
 
 
10 
 
Figure 6: Results of Literature Search 
 
 
Of the five articles identified, two were written by individuals directly engaged with PEPFAR 
(Ambassador Eric Goosby, US Global AIDS Ambassador and head of OGAC) and GF (Ms. Natasha 
Bilimoria, former President of the Friends of the Global Fight Against AIDS, Tuberculosis, and Malaria); 
two of the articles were written by academics, and one was written by a public policy researcher at the 
Congressional Research Service. While three of the articles reviewed global trends and impact, the other 
two (Hirsch et al, 2015; Bilimoria, 2012) focused on country case studies of Vietnam and Tanzania, 
respectively. Two of the articles (Bilimoria, 2012 and Goosby, 2012) focused solely, explicitly on the 
relationship between PEPFAR and GF; no articles were found that analyzed the relationship between 
CDC and GF specifically, or between PMI and/or TB Care and GF.  
Table 3 below summarizes the characteristic of the articles included in this literature review.  
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Table 3: Articles Included in Review 
Article Authors Affiliation(s) Approach 
The effects of global health initiatives on 
country health systems: a review of the 
evidence from HIV/AIDS control 
Biesma, et al. 
(2009) 
UK universities  Systematic 
review 
Lessons Learned from A Decade 
Of Partnership Between 
PEPFAR and the Global Fund: 
A Case Study from Tanzania 
Bilimoria 
(2012) 
Board of Directors, 
Friends of the GF 
Case study 
(based on key 
informant 
interviews) 
The Way Forward: Maximizing Our 
Impact Through Shared 
Responsibility and Smart Investments 
Goosby 
(2012) 
Global AIDS 
Ambassador (USG, 
OGAC) 
Policy analysis 
and opinion  
Caught in the Middle: 
The Contested Politics of HIV/AIDS 
and Health Policy in Vietnam 
Hirsch, et al. 
(2015) 
US and Vietnam 
universities 
Case study and 
historical review 
U.S. Global Health Assistance: 
Background and Issues for the 113th 
Congress 
Salaam-
Blyther 
(2013) 
Congressional 
Research Service 
Policy and 
financial 
analysis 
 
 After reviewing the selected articles several times for major themes and commonalities, it became 
clear that most or all of them covered three main elements: the nature of engagement beteween the 
entities, best practices for cooperation, and recommendations for improved coordination. This literature 
review captures key findings and analyses from the five articles in these areas.  
12 
 
NATURE OF ENGAGEMENT 
Bilimoria provided the most detailed analysis of the day-to-day engagement between PEPFAR 
and GF, describing the frequency and types of communication (e.g., weekly phone calls, field visits), 
program coordination, and grant oversight between the two parties at the country level (largely in 
Tanzania, but also in Ethiopia and Zambia). Others, including Goosby (2012), posed questions and 
offered strategies (e.g., greater financial transparency and analysis, streamlining of operations) for 
enhancing partnerships but did not provide details on how such engagement currently occurs at the HQ or 
country levels. Similarly, Salaam-Blyther (2013) described the pros and cons of investment in GF and 
other multilaterals, compared to solely bilateral (i.e., PEPFAR, PMI, and TB Care) funding. The Biesma, 
et al (2009) systematic review highlighted the lack of harmonization in planning and funding between GF 
and other partners across countries, as well as challenges in divergent policies related to supply chain and 
support for civil society and health systems strengthening. Similar issues related to differences in the 
types of host country government engagement and technical priorities were also highlighted by Hirsch 
and colleagues (2015).  
BEST PRACTICES 
 Only Bilimoria (2012) and Biesma (2009) identified best practices in USG and GF collaboration 
generally. These included greater stakeholder collaboration through planning and oversight processes 
(i.e., the CCM), and coordinated timing of disbursements to prevent gaps in funding of essential services. 
In Tanzania, joint planning and procurement helped avoid stock-outs of essential commodities (e.g., 
antiretroviral drugs, HIV test kits) and reduced drug theft and expiry. According to Biesma (2009), 
multiple countries benefited from enhanced communication and sharing of plans, as it produced greater 
transparency, accountability, and ability to anticipate future needs. In addition, Bilimoria (2012) cited 
USG participation in the CCM and grant application processes, as well as jointly funded projects, as 
successes in Tanzania as they improved program operations and oversight.  
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RECOMMENDATIONS 
 Based on the Tanzania case study, Bilimoria (2012) offered several technical recommendations 
for enhanced engagement, including sustained communication, allocating increased resources to oversight 
structures in-country, and greater alignment between national strategies. Hirsch and colleagues’ (2015) 
recommendations largely revolved around the timing and approach to policy intervention by donors (i.e., 
joint agreement on program priorities, geographic areas of focus), including USG and GF, but do not 
discuss how they should coordinate efforts.  
DISCUSSION AND LIMITATIONS 
My review indicates a dearth of analysis on collaboration between USG and GF, with the 
exception of a few articles regarding work on HIV/AIDS. Overall, the articles included in this literature 
review did not examine, in detail, the ways in which the USG (and CDC in particular) and GF engage 
across countries and HQ, and could only provide examples from a few countries to support their general 
claims. While much of the focus has been on prior types of engagement, very little has been done to 
consider future, alternative means of collaboration, especially as USG and GF reform their own 
approaches to global health and set new priorities.  
From my review of the existing literature, it is clear that there has been no systematic, holistic 
documentation and analysis of the dynamic between CDC and GF. My research sought to fill that gap and 
more fully describe the relationship between these two global players. The goal of this study was to 
examine current engagement by CDC with GF and detail strategies for improvement. More specifically, 
the primary, overarching research question of this study was: How can CDC improve collaboration with 
the Global Fund at HQ and country levels in order to increase the impact of health investments by both 
entities?  
The aims of this study were: 
• To describe the current nature of CDC engagement in Global Fund processes and structures at 
HQ and country levels.  
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• To characterize levels of knowledge of the Global Fund among CDC staff and determine areas 
for enhanced understanding.  
• To detail the current mode and frequency of communication between CDC and the Global Fund, 
as well as other stakeholders. 
• To identify best practices and lessons learned to date among CDC staff regarding Global Fund 
collaboration.  
 From my experience as a policy advisor in three CDC overseas offices and now as the Associate 
Director for Policy for a CDC global health division, I have a deep interest and experience with this 
subject. Having been a part of the development of several CNs and a member of CCM subcommittees, I 
have witnessed many of the challenges and opportunities associated with GF, as well as with CDC’s 
approach to supporting the institution. Many colleagues in the field and at CDC HQ have had similar 
experiences and insights, and I feel invested in documenting their knowledge and recommendations in 
order to improve GF collaboration for all CDC staff and to increase the impact of our shared public health 
efforts.  
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CHAPTER 3: METHODOLOGY 
DISSERTATION AIMS AND RESEARCH QUESTIONS 
The primary, overarching research question of this study was: 
• How can CDC improve collaboration with the Global Fund at HQ and country levels in order to 
increase the impact of health investments by both entities? 
Following are the aims and associated data and methods of my study:  
1. To describe the current nature of CDC engagement in Global Fund processes and structures at 
HQ and country levels.  
a. Methods: secondary analysis of a quantitative survey; key informant interviews 
2. To characterize levels of knowledge of the Global Fund among CDC staff and determine areas 
for enhanced understanding.  
a. Method: secondary analysis of a quantitative survey 
3. To detail the current mode and frequency of communication between CDC and the Global Fund, 
as well as other stakeholders.  
a. Method: secondary analysis of a quantitative survey; key informant interviews 
4. To identify best practices and lessons learned to date among CDC staff regarding Global Fund 
collaboration  
a. Method: secondary analysis of a quantitative survey; key informant interviews to develop 
a plan for change 
 I utilized quantitative and qualitative data collected from CDC staff in two stages to broadly 
assess current CDC engagement with GF at various levels. This methodology and associated materials 
were approved the UNC Institutional Review Board and the CDC Center for Global Health Science 
Office. In the first stage, I analyzed largely quantitative secondary data which I collected through a 
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targeted online, 51-question survey (via SurveyMonkey) from May to July 2015. This survey was 
distributed by the CDC Center for Global Health Director at that time, Dr. Thomas Kenyon, to all staff in 
that Center (which included almost all country office staff) and individuals in other Centers working on 
global health. 
Figure 7 below presents the current [2018] CDC operating sections in which respondents to the 
quantitative survey primarily work. CDC staff seconded to the World Health Organization (WHO), Joint 
United Nations Program on HIV/AIDS (UNAIDS), and other institutions are not represented in this figure 
but may have been included in the survey or interviews.  
Figure 7: Current CDC Operating Units of Most Survey Respondents 
 
Note: A few of the survey respondents were from other units within CDC or seconded to other 
organizations. The distribution of respondents is detailed in Chapter 4.  
 
 I analyzed data from the online survey using Excel and presented in tables, charts, and map 
formats (see Chapter 4).  
In the second stage, I collected additional qualitative data through nine key informant interviews 
(KIIs; see Appendix C for sample questions) with CDC staff heavily engaged with GF at the policy and 
technical levels, including those seconded to GF. I analyzed data from the nine key informant interviews 
using thematic coding and integrated results into the overall description of findings and recommendations. 
This mixed methods approach harnessed CDC insights and inputs for both CDC and GF policy 
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development, as well as informed ways to strengthen collaboration and ensure continuous reform. I 
conducted this research sequentially to establish a baseline understanding of current engagement and 
inform the content and approach of the KIIs.  
I used snowball sampling to identify interviewees. I selected the first three interviewees based on 
personal knowledge of their high level of experience with GF; two were in CDC country offices, and one 
was at CDC HQ. After the sessions with the three initial interviewees I asked each of them to recommend 
two to three other people who may be interested in participating or have unique perspectives on the GF 
partnership. I contacted all interviewees via email, with a standardized introduction describing the 
purpose of the research, expectations for the interview, and mechanisms for ensuring confidentiality of 
responses, as well as providing the written consent form. The email explained that they are not obligated 
to participate and that declining would have no effect on their professional relationships. A second email 
followed one week after the first if no response was received. If no contact was established, an alternate 
interview was identified through the network of those who have already participated. A few of the 
individuals contacted referred the email to a colleague who they believed would be better suited to the 
interview; these new referrals were then contacted per the protocol above.  
When participants agreed to be interviewed, I scheduled a convenient appointment time. I 
conducted the interview by phone for all participants. With participant permission, I recorded all sessions 
and obtained written consent from the interviewee at the time of the phone interview. I reviewed the 
consent form orally and invited the participant to ask questions about the study. I obtained consent and 
interviewed all study participants in English. I described all of my study procedures in detail so that the 
participant was fully informed as to their options for participating in this study. 
During this consent process, I reminded subjects they were free to choose to take part in the 
research study or not, and that their decision would not affect their employment at CDC. The potential 
participants were able to agree or decline to participate in the study at that time; all those contacted via 
phone agreed to participate. Those who consented to participate in the study were interviewed. During the 
consent process, I informed participants that information they provide through interviews was 
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confidential (i.e., not shared with anyone outside of the research team) and voluntary (i.e., they were not 
obligated to answer any question). Interviewees were told that they were free to take breaks and/or 
terminate the interview at any time. The interviews lasted from 20 to 75 minutes and were comprised of a 
series of open-ended questions about their experience working with GF and suggestions for enhanced 
collaboration. 
To maintain confidentiality, I gave each subject a random numeric identifier so their specific 
comments could not be linked to the data. Given the small sample size, there were instances where the 
respondents’ identities could be known, based on their examples or perspectives. In these situations, I 
made every effort to convey the information without revealing identifying details of the respondents (e.g., 
stating that the respondent works in a sub-Saharan African country rather than naming the specific 
country). Immediately after each interview, the digitally recorded files were uploaded and saved on a 
password-protected and encrypted computer continuously in my possession. I transcribed interview files 
and did not transfer the recordings to anyone else. I transcribed interviews verbatim and verified them 
against the audio recording to ensure that all thoughts and opinions were accurately reflected in the 
analysis. Once verification of the transcripts was complete, I conducted a content analysis, which 
involved identifying themes and categories prior to coding the data. Coding was done by reviewing 
transcripts of all the interviews in Word and color-coding them based on the pre-identified themes. A 
fellow doctoral student, not involved in the study, verified the coding by reviewing a sample of three 
coded interviews and provided feedback on the approach. This feedback was incorporated by adjusting 
the initial coding for the sample interviews and applied to all further coding. Following the coding of all 
interviews, I generated coding reports for each of the codes in order to systematically analyze and report 
on the information received during the key informant interviews. 
Once the data were analyzed and the study completed, all recordings were destroyed to ensure 
that no responses would be linked to an individual. The results were presented in the aggregate and the 
names of the individuals kept confidential. General descriptors of key informants were included, but in 
order to maintain confidentiality of the respondents, the participants’ names were not included. No hard 
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copies of any materials were collected from the interviewees or the survey participants. All interview data 
was stored in a password protected and encrypted computer in the continuous possession of the principal 
investigator. 
While it would have been preferable to include GF individuals among the key informants, after 
consultation with several individuals at CDC, USAID, and the Department of State, it was determined not 
to be feasible or appropriate to officially interview GF staff for this project. However, unofficial 
consultation with a few GF staff or secondees was done after the analysis was completed to confirm the 
appropriateness of recommendations.  
SURVEY DATA 
Table 4 shows the categories of the quantitative survey respondents. The key informant interview 
subjects were drawn from these groups, based on analysis of the survey data and identified gaps or areas 
for further exploration.  
Table 4: Targeted CDC Respondents to Online Survey, May—July 2015 
Category HIV TB Malaria 
HQ Leadership 
DGHT Director, Branch 
Chiefs 
DGHT and DTBE 
Directors, Branch Chiefs 
DPDM Director, Branch 
Chiefs, PMI Lead 
HQ Technical 
DGHT Technical Staff, 
GF, UNAIDS and WHO 
Secondees 
DTBE Technical Staff, 
GF and WHO Secondees 
DPDM Technical Staff, 
GF and WHO Secondees 
Field 
Leadership 
Country, Program 
Directors 
Country, Program 
Directors 
Country Director 
Field Technical 
CDC/PEPFAR Team 
Leads, HIV Technical 
Advisors, GF Liaisons 
CDC/PEPFAR Team 
Leads, TB Advisors, GF 
Liaisons 
PMI Resident Advisors, 
GF Liaisons 
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ANALYSIS OF FINDINGS 
 Once the full quantitative analysis of the survey data and the qualitative thematic coding of the 
KIIs was complete, the results were reviewed together to identify common themes, patterns, and trends, 
as well as areas of divergence. Quotes from the KIIs were used to illuminate or expand on findings from 
the survey data, offer explanations for results, or provide different perspectives. The findings were 
presented jointly by theme, with the most critical results and recommendations shared first by domain.  
DATA TABLES 
The results of the survey were broken into several thematic categories. Based on the content of 
the 51-question survey, categories include: characteristics of the survey respondents, support for 
development of Concept Notes, engagement with the CCM, collaboration with other stakeholders, 
external and internal communication, staffing and knowledge, and future CDC technical assistance.  
LIMITATIONS 
 Although there are two parties in this relationship—CDC and GF—only one set of perspectives 
(those of CDC staff) were included in this analysis. Because GF staff could not be surveyed or 
interviewed officially for this study, it was not possible to obtain their views on how CDC engages with 
GF processes or how GF engages with CDC systems. In addition, this study utilized survey data collected 
in 2015, which may be dated by the time the recommendations can be enacted, particularly if major 
changes are made to GF policies or technical approaches. New CDC staff, developments in global health, 
and changes in country dynamics may also make these findings less relevant than if this study had been 
published immediately after the survey was conducted. Next, the limit of nine KIIs does not allow for the 
full range of perspectives to be presented and some viewpoints or recommendations may be inadvertently 
omitted. Finally, the researcher’s own experiences may bias the results, even with every effort made to 
preserve objectivity.  
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CHAPTER 4: RESULTS 
SURVEY AND INTERVIEW RESPONDENTS 
Between May 26 and June 15, 2015, a total of 144 individuals completed some or all of the 
survey. Of the respondents, 82 (56%) were based in CDC country offices, 47 (33%) were based at CDC 
Headquarters, 8 (6%) were CDC staff placed in other institutions, and 7 (5%) reported “Other” 
locations/functions.12 Forty-one (28%) of respondents were in leadership positions and 88 (61%) were in 
technical positions, with the remainder secondees or responding “Other”. Figure 8 summarizes the 
respondents’ current location and main function.  
Figure 8: Respondents' Current Location and Main Function (N=144) 
 
In terms of organization or office, the vast majority (123; 88%) of respondents came from CGH 
Divisions, with an additional six respondents (4%) coming from the CGH OD. DGHT accounted for 61% 
                                                          
12The seven individuals responding “Other” wrote in the following answers: CDC Country Office Technical 
Support; Overseas; CDC Secondee to the Global Fund Secretariat; CTS Contractor, PEPFAR Global Fund Liaison; 
CDC OD; Administrative Assistant; I am not involved in management. For ease of analysis, this group was merged 
with “CDC HQ & Secondees”. 
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of all respondents, including 82% of field respondents, which was expected given the field presence of the 
division. In addition to respondents from WHO (3) and GF (2), participants also came from 
NCHHSTP/DSTD (2), DOS/PEPFAR Coordination Office (1), PEPFAR— GF Liaison (1), 
NCHHSTP/DTBE (1), DOD/DHAPP (1). Figure 9 summarizes the current organization or office of the 
respondents.  
Figure 9: Respondents’ Current CDC Organization/Office (N=140) 
 
 
There was geographic diversity among the respondents, with 42 countries or regions represented. 
Figure 10 highlights in turquoise the stated work locations of the survey respondents.  
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Figure 10: Respondents' Current Work Location 
 
Countries/regions stated: Barbados, Botswana, Burma, Cambodia, Cameroon, Central Asia Region, Chad, China, 
Cote d’Ivoire, Democratic Republic of Congo, Dominican Republic, Ethiopia, Georgia, Ghana, Guatemala, Guinea, 
Haiti, India, Kenya, Kyrgyz Republic, Lesotho, Liberia, Malawi, Mali, Mozambique, Namibia, Nigeria, Papua New 
Guinea, Philippines, Rwanda, Senegal, South Africa, Swaziland, Switzerland, Syria, Tanzania, Thailand, Uganda, 
U.S., Vietnam, Zambia, Zimbabwe 
 
Similarly, interviewees had experience in a range of regions, including Southeast Asia, South 
Asia, and sub-Saharan Africa. Between them, they served in nine countries for CDC, with four also 
serving at CDC HQ. Three had experience working in Switzerland with GF and other multilaterals. 
Interviewees had worked for CDC as U.S. direct hires, contractors, and locally employed staff. HIV was 
the major component of all interviewees’ work, but the majority reported covering TB and malaria as 
well.  
KEY FINDINGS 
 Major findings of the survey are listed below, by domain. These findings were all confirmed and 
reinforced through the key informant interviews. 
1. History with the Global Fund: CDC staff, particularly those in the field, consider GF very 
important to their work and have a high level of interest in GF activities.  
a. Over 80% of respondents reported that GF is “Very Important” (55%) or “Important” 
(25%) to their work; rates for field staff were 57% and 24%, respectively.  
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b. Almost 70% of respondents reported a “Very High” (38%) or “High” (31%) level of 
interest in GF; 74% of field staff reported such levels of interest (38% and 36%, 
respectively).  
2. Support for Development of Concept Notes: CDC staff engage in all aspects of GF, especially the 
development of Concept Notes (CNs) but efforts are not necessarily maximally effective. 
a. CDC staff engage in key ways with GF, including “Technical assistance for development 
of Concept Notes” (60%), “Coordination with USG/CDC initiatives” (60%), “Technical 
assistance for development of National Strategic Plans” (56%), “Discussion with Country 
Coordinating Mechanisms [CCMs]” (52%), and “Support for implementation of Global 
Fund activities” (45%).  
b. Level of engagement is significant, as 44% of respondents considered their engagement 
with the development of Concept Notes “Very substantial” (14%) or “Substantial” 
(30%); rates for field staff were higher, at 19% and 38%, respectively.  
c. Overall, a low proportion (40%) of respondents considered themselves “Very effective 
(11%) or “Effective” (29%) at influencing the content of Concept Notes; rates among 
field staff were higher, at 15% and 35%, respectively, compared to 6% and 21% for HQ 
and secondee staff.  
3. Engagement with the Country Coordinating Mechanism: Working with the CCM was named the 
most common way that CDC staff interacted with GF but CDC did not necessarily have a formal 
role or position on the CCM.  
a. CDC participated in the CCM in various ways, including as a voting member (39%), non-
voting member (20%), and/or member of a CCM sub-committee (27%).  
b. However, the reported rate of CDC having a dedicated permanent (21%) or alternate 
(13%) seat was relatively low, with CDC most commonly (31%) rotating into a 
permanent seat with another USG agency. 
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4. Coordination with Other Stakeholders: Engagement by Ministries of Health in GF activities is 
particularly high, but not necessarily technically or strategically robust.  
a. Over 90% of respondents reported engagement by the Ministry of Health as “Very High” 
(77%) or “High” (13%).  
b. Only 45% of respondents reported the quality of technical or strategic contributions from 
the Ministry of Health as “Very Good” (20%) or “Good” (25%). Thirty-eight percent 
reported the quality as “Average”, 13% as “Poor”, and 4% as “Very Poor”.  
5. External and Internal Communication: The exchange of information with GF teams and within 
CDC is largely irregular or infrequent, and highly dependent on proactive outreach or personal 
connections.  
a. In terms of external communication, phone calls with the FPMT seem to be largely ad 
hoc (52%) or never (29%). The case seems to be similar for in-person meetings, with 
53% reporting only ad hoc meetings and 26% reporting never meeting with the FPMT. 
b. Over 65% of HQ staff and 51% of field staff reported being in contact on GF matters 
only once or twice a year, with an additional 8% of HQ staff and 25% of field staff 
stating that they are never in touch with each other on such issues.  
c. This situation may be due in part to a lack of official points of contact at HQ on GF 
issues or updates, as only 15% of field staff reporting having such a contact. Almost half 
(48%) reported not having such an official contact nor reaching out unofficially to any 
HQ staff on regarding GF. 
6. Staffing and Knowledge: Despite substantial involvement, CDC does not have dedicated staff to 
engage with GF. In general, CDC staff have not received formal training on GF and generally rate 
their level of knowledge as relatively low. Field staff in particular are very interested in learning 
more about GF systems and processes.  
a. Over 93% of respondents reported that their offices do not have a CDC staff person 
dedicated full-time to GF activities.  
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b. Overall, 60% of staff reported never having received training from any source on GF, 
including 63% of field respondents.  
c. On a scale of 1 to 5 (with 1 being “low” and 5 being “excellent”), on average CDC staff 
rated their knowledge various aspects of GF as 2.59, ranging from 2.40 for “Global Fund 
decision-making” to 2.82 for “Concept Note development”. Among field staff the 
average rating was slightly higher, at 2.68, ranging from 2.40 for “Global Fund decision-
making” to 3.13 for “Concept Note development”.  
d. In terms of interest in learning more about GF, on a scale of 1 to 5 (with 1 being “not 
interested” and 5 being “extremely interested”), on average CDC staff rated their interest 
as 3.82, with topical interest ranging from 3.62 in “Governance of The Global Fund” to 
4.03 in “Global Fund monitoring and evaluation standards”. Field staff rated their overall 
interest as 3.94; topical interest ranged from 3.70 in “Governance of The Global Fund” to 
4.23 in “Global Fund monitoring and evaluation standards”.  
7. Future Technical Assistance: CDC staff think that if additional funds were made available, 
additional staff should be placed in-country to assist with GF on multiple technical and strategic 
elements.  
a. If additional funding were available for technical assistance to GF, CDC staff believe that 
the funding should support “CDC staff in country offices” (45%) or “CDC staff seconded 
to the Principal Recipient(s)” (41%).  
b. Major elements that CDC staff think the agency should provide technical assistance on 
include “Epidemiologic analysis and target-setting” (91%), “Laboratory systems 
planning” (84%), “Disease-specific program interventions” (79%), “Strategic planning” 
(75%), “Program M&E” (71%), and “Quality improvement systems” (70%).  
These findings are described in more depth in the following sections.  
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HISTORY WITH THE GLOBAL FUND 
Tables 5 and 6 present the reported years of work with CDC and engagement with GF. Overall, 
the survey respondents worked for CDC for a relatively long period, with 48% of field staff and 49% of 
HQ staff reporting ten or more years of work with the agency. However, both CDC field and HQ staff 
have been engaged with GF for a shorter period, with 47% and 45% reporting three or fewer years of 
engagement, respectively.  
Table 5: Number of Years of Work with CDC 
Response (N=141) 
CDC Field Staff 
n (%) 
CDC HQ & Secondee Staff 
n (%) 
All CDC Staff 
n (%) 
Less than one year 8 (10%) 0 (0%) 8 (6%) 
1-3 years 18 (23%) 11 (18%) 29 (21%) 
4-6 years 6 (8%) 12 (20%) 18 (13%) 
7-9 years 10 (13%) 8 (13%) 18 (13%) 
10-12 years 15 (19%) 8 (13%) 23 (16%) 
13+ years 23 (29%) 22 (36%)  45 (32%) 
 
Table 6: Number of Years of Involvement with Activities Related to the Global Fund 
Response (N=141) 
CDC Field Staff 
n (%) 
CDC HQ & Secondee Staff 
n (%) 
All CDC Staff 
n (%) 
Less than one year 9 (11%) 12 (20%) 21 (15%) 
1-3 years 29 (36%) 15 (25%) 44 (31%)  
4-6 years 24 (30%) 14 (23%) 38 (27%) 
7-9 years 12 (15%) 12 (20%) 24 (17%) 
10-12 years 5 (6%) 3 (5%) 8 (6%) 
13+ years 2 (2%) 4 (7%) 6 (4%) 
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CDC staff, both in the field and at HQ, consider GF very important to their work and have a high 
level of interest in GF activities, as captured in Tables 7 and 8. Approximately 80% of respondents 
reported that GF is “Very Important” (55%) or “Important” (25%) to their work; rates were slightly 
higher for field staff (81%) compared to HQ staff (77%). Similarly, almost 70% of respondents reported a 
“Very High” (38%) or “High” (31%) level of interest in GF; 74% of field staff reported such levels of 
interest compared to 63% of HQ staff.      
Table 7: Importance of the Global Fund to Their Work 
Response (N=142) 
CDC Field Staff 
n (%) 
CDC HQ & Secondee Staff 
n (%) 
All CDC Staff 
n (%) 
Very Important 47 (57%) 31 (52%) 78 (55%) 
Important 20 (24%) 15 (25%) 35 (25%) 
Somewhat Important 12 (15%) 7 (12%) 19 (14%) 
Not Important 3 (4%) 7 (12%) 10 (7%) 
 
Table 8: Level of Interest in the Global Fund 
Response (N=141) 
CDC Field Staff 
n (%) 
CDC HQ & Secondee Staff 
n (%) 
All CDC Staff 
n (%) 
Very High 31 (38%) 23 (38%) 54 (38%) 
High 29 (36%) 15 (25%) 44 (31%) 
Moderate 16 (20%) 15 (25%) 31 (22%) 
Low 4 (5%) 3 (5%) 7 (5%) 
None 1 (1%) 4 (7%) 5 (4%) 
 
Interviewees echoed these sentiments, stating that they considered GF a critical partner and 
extremely important to their work. Many cited the fact that USG is “the major investor in GF” as 
additional motivation to engage with GF. Others had previously worked for organizations implementing 
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GF grants or for the Local Fund Agent in country and wanted to maintain interaction with GF, even in 
their new role with CDC.  
CDC staff support all types of GF grants (Table 9), even if their office may not receive funding 
for a particular disease program. Although 82% of respondents work for DGHT (with HIV/AIDS money), 
there was a high level of support for HIV/TB grants (57% for field staff), malaria grants (33%), and 
health systems strengthening grants (31%), indicating that country offices in particular are providing 
technical assistance on grants beyond their own funding stream(s). Several respondents documented this 
arrangement, stating that they contributed to the technical development of a Concept Note (CN) for 
program that did not receive USG funds in their country (e.g., a malaria CN when they only receive HIV 
and TB funding). Individuals serving as GF liaisons also reported that while their salaries were paid for 
by HIV funding, they covered all grants and disease areas.  
Table 9: Types of Global Fund Grants on Which CDC Staff Engage 
Response (N=85); 
multiple responses 
allowed 
CDC Field Staff 
n (%) 
CDC HQ & Secondee Staff 
n (%) 
All CDC Staff 
n (%) 
HIV only 22 (43%) 19 (56%) 41 (48%) 
TB only 6 (12%) 8 (24%) 14 (16%) 
HIV/TB 29 (57%) 13 (38%) 42 (49%) 
Malaria 17 (33%) 9 (26%) 26 (31%) 
Health Systems 
Strengthening 
16 (31%) 6 (18%) 22 (26%) 
 
In terms of types of collaboration with GF, the principal forms of engagement overall were 
“Coordination with USG/CDC Initiatives” (60%), “Technical Assistance for Development of Concept 
Notes” (60%), “Technical Assistance for Development of National Strategic Plans” (56%), “Discussions 
with Country Coordinating Mechanisms” (52%), and “Support for Implementation” (45%), as captured in 
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Table 10. Field staff reported higher levels of engagement in all areas, with the exception of “Site Visits 
to Global Fund Sites” (29% for field staff, 36% for HQ staff) and “Other”; responses for the latter 
category were focused on high level diplomatic conversation and resource mobilization. The finding on 
site visits is unexpected and may warrant further exploration.  
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Table 10: Engagement with Types of Global Fund Activities 
Response (N=87; multiple 
responses allowed) 
CDC Field Staff 
n (%) 
CDC HQ & Secondee Staff 
n (%) 
All CDC Staff 
n (%) 
Coordination with 
USG/CDC initiatives 
34 (67%) 13 (50%) 52 (60%) 
Technical assistance for 
Concept Notes 
32 (63%) 20 (56%) 52 (60%) 
Technical assistance for 
National Strategic Plans 
29 (57%) 20 (56%) 49 (56%) 
Discussion with CCMs 32 (63%) 13 (36%) 45 (52%) 
Support for 
implementation 
30 (59%) 9 (25%) 39 (45%) 
Site visits to GF sites 15 (29%) 13 (36%) 28 (32%) 
Technical assistance for 
M&E of GF activities 
15 (29%) 9 (25%) 24 (28%) 
Implementation of surveys 20 (39%) 3 (8%) 23 (26%) 
Member of the CCM 14 (27%) 2 (6%) 16 (18%) 
Technical assistance to 
Technical Review Panel  
9 (18%) 4 (11%) 13 (15%) 
Resolution of Conditions 
Precedent/Management 
Actions 
6 (12%) 1 (3%) 7 (8%) 
Participation in mock TRP 4 (8%) 1 (3%) 5 (6%) 
Other 5 (10%) 7 (19%) 12 (14%) 
“Other” included: TA to MOH to implement GF activities; CCM reform; CCM oversight improvement; 
coordination with NGOs; member of oversight committee; HIV Impact Assessment; high level diplomatic 
coordinated host country engagement; resource mobilization with GF HQ 
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 In the key informant interviews, the most common phrase used to describe CDC’s role in all 
engagement with GF was “technical assistance.” Because GF has no in-country presence, CDC staff 
describe CDC as the primary technical resource for all GF matters. One interviewee summed it up by 
saying: 
“There are numerous areas where CDC has a natural synergy with GF. I think the 
strongest role for CDC is in bringing to bear technical assistance in the 
monitoring and improvement of the implementation of GF grants, in addition to 
the design and consultation phase. For example, in my country, the CDC Care 
and Treatment Branch Chief and Deputy Director for Programs worked very 
closely in the design of the grant. Each Technical Working Group had CDC staff 
on them, looking at what PEPFAR is doing, what CDC is doing as part of 
PEPFAR, and helping formulate the proposal. Once the grants were 
implemented, our Strategic Information teams would weigh in to validate 
program data and the performance framework to help ensure that everything is 
tracking well and that we aren’t duplicating efforts. On the program management 
side, the Cooperative Agreement Branch Chief and Strategic Information Branch 
Chief worked closely with GF staff in country to ensure that the disease packages 
made sense and grantees were doing the work.” 
 
 Likewise, another interviewee said, “CDC has so much technical expertise in these countries and 
we leverage that expertise to help make sure that the funding goes to the right areas and the right places 
and the right programs.” Another stated that “Our role is to provide continuous technical assistance to 
ensure that programs are up to standard and generating value for the money invested.” CDC’s technical 
acumen was seen as a point of pride and asset the USG, as it was in demand by the country. “The degree 
to which technical assistance is needed depends on the country. We didn’t write the grant for my country 
but we were at the table. CDC has the analytic skills and scientific knowledge that are desired by the 
government,” said another interviewee.  
SUPPORT FOR DEVELOPMENT OF CONCEPT NOTES 
Development of Concept Notes was reported was one of the two most frequent ways CDC staff 
engage on GF issues. Table 11 reflects the elements of the Concept Note to which CDC staff contribute, 
with “Programmatic Gap” (69%), “Country Context” (68%), and “Modular Template: Concept Note” 
(48%) being the most common. Levels of engagement were higher for CDC field staff compared to HQ 
staff in all area, with the exception of “Funding Landscape, Additionality, and Sustainability” (38% for 
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field staff, 50% for HQ staff). This may indicate a weakness in capacity of field staff to support this 
element and an area for increased focus.  
Table 11: Input Provided to Sections of Concept Notes 
Response (N=62; multiple 
responses allowed) 
CDC Field Staff 
n (%) 
CDC HQ & Secondee Staff  
n (%) 
All CDC Staff 
n (%) 
Programmatic Gap 28 (70%) 15 (68%) 43 (69%) 
Country Context 28 (70%) 14 (63%) 42 (68%) 
Modular Template: 
Concept Note 
20 (50%) 10 (45%) 30 (48%) 
Funding Landscape, 
Additionality, and 
Sustainability 
15 (38%) 11 (50%) 26 (42%) 
Modular Template: 
Targets 
17 (43%) 7 (32%) 24 (39%) 
Modular Template: 
Program Framework 
14 (35%) 7 (32%) 21 (34%) 
Implementation 
Arrangements and Risk 
Assessment 
15 (38%) 6 (27%) 21 (34%) 
Financial Gap Analysis 14 (35%) 5 (23%) 19 (31%) 
Modular Template: 
Summary Budget 
10 (25%) 3 (14%) 13 (21%) 
Other 7 (18%) 3 (14%) 10 (16%) 
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The interviews with CDC staff revealed that they do a significant amount of background work in 
preparation for the CNs. Said one, “Before the CN writing begins, we do a PEPFAR portfolio analysis, 
look at where and what PEPFAR is doing, and where GF complementary support is needed so that we can 
ensure this is incorporated when the CN is written.” Another interview similarly highlighted engagement 
throughout the process, saying “Engagement is much higher during a CN year. Before starting the CN, we 
help develop the desk reviews of strengths and gaps. We then help develop the application, answer 
questions, prepare for defense, get set for implementation, and align the CN with our own COP.” CDC 
HQ was also critical to the preparation for CNs, with one interviewee explaining that, “This year we got 
support from CDC HQ on multiple levels. For the desk reviews, the TB one was done by a CDC HQ 
TDYer who came out to country, and the HIV one was supported remotely. They also provided support 
on the components of the CN and helped with the negotiation around procurement of commodities.”  
CDC’s level of engagement in the development of Concept Notes (Table 12) was significant, as 
54% of respondents considered their engagement with the development of Concept Notes “Very 
Substantial” (14%) or “Substantial” (30%); rates for field staff were higher, at 19% and 38%, 
respectively. However, per Table 13, overall only 40% of respondents considered themselves “Very 
Effective (11%) or “Effective” (29%) at influencing the content of Concept Notes; rates among field staff 
were slightly higher, at 15% and 35%, respectively. Even for field staff, a self-described effectiveness rate 
of 50% indicates room for improvement, especially given that only 15% consider themselves very 
effective.  
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Table 12: Level of Engagement in Concept Note Development 
Response (N=81) 
CDC Field Staff 
n (%) 
CDC HQ & Secondee Staff 
n (%) 
All CDC Staff 
n (%) 
Very Substantial 9 (19%) 2 (6%) 11 (14%) 
Substantial 18 (38%) 6 (18%) 24 (30%) 
Active but Not Substantial 9 (19%) 8 (24%) 17 (21%) 
Limited 6 (13%) 11 (32%) 17 (21%) 
None 5 (11%) 7 (21%) 12 (15%) 
 
Table 13: Effectiveness at Influencing Concept Note Development 
Response (N=79) 
CDC Field Staff 
n (%) 
CDC HQ & Secondee Staff 
n (%) 
All CDC Staff 
n (%) 
Very Effective 7 (15%) 2 (6%) 9 (11%) 
Effective 16 (35%) 7 (21%) 23 (29%) 
Somewhat Effective 16 (35%) 10 (30%) 26 (33%) 
Not Effective 3 (7%) 7 (21%) 10 (13%) 
Don’t Know 4 (9%) 7 (21%) 11 (14%) 
  
Interviewees also felt that there was room for growth in terms of impact and the effectiveness of 
CDC engagement. One staff member highlighted the gap between technical and strategic level impact and 
offered a potential explanation, saying: 
“Our effectiveness is a different story. CDC can be very effective it comes to certain 
specific technical aspects, like HIV self-testing. PEFPAR can really influence at the 
country, CCM, and technical levels to show them the data from our programs, what we 
have done in other countries and encourage them to include in their grants. At both the 
local and Geneva levels we have potential to have even more influence but whether we 
do depends on personalities—who among the CDC country and HQ staff engage with 
GF, how much they know about GF systems and processes and what’s possible and 
what’s not. CDC needs to do better in understanding how GF thinks as a financial 
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mechanism and understanding how you influence that thinking; that’s something that not 
all CDC staff naturally know.” 
 
 Several other interviewees mentioned the different levels of knowledge and perspectives between 
GF and CDC, and the challenge of making change happen: 
“The challenge on CDC side is not understanding that GF is not highly technical across 
the institution, that it’s not the core mentality of the institution. So when we engage with 
the Fund they are thinking about risk management and ease of financial 
implementation—that’s a different argument structure. You can bring in technical 
information but need to sell them that this will improve execution of funds, anticipate 
their concerns, show them that they can have program impact and not risk financial 
mismanagement. That’s something we can do better at in country and Geneva, learn to 
speak their language, not fall down the technical rabbit hole right away. It takes patience 
and time and getting used to it; we can’t get frustrated. Especially for PEPFAR, which is 
looking at such a vast amount of data at such a granular level, compared to watching the 
Fund lumber through the very basic indicators of their performance framework and 
watching them fund things which may not be validated programmatically can be difficult 
for our CDC staff.” 
 
“Technocrats in CDC, like myself, are quite noisy people who point out what needs to be 
done in terms of resource use efficiency and technical implementation; we make noise in 
TWGs, CCMs, and with PRs so that things get done in most impactful ways. At the end 
of the day things get done but it’s quite a struggle. We work through this lobbying 
process and spend a lot of time doing the analysis so we can present a compelling case. 
We have had significant impact but perfection is difficult to achieve. In terms of our 
lobbying of GF, sometimes we’re successful and sometimes we’re not.”  
 
However, some interviewees felt that they were able to effectively influence GF. One said, “The 
process was very rewarding, as we were able to promote cost-effectiveness and appropriate attribution. 
We prevented co-location so everyone is not in the same place but is working from similar strategies. 
Working with GF and the government allows us to support CDC objectives and stop double counting.” 
Another explained, “Our engagement was very effective. First we made sure the MOH was on board with 
our intended use of the GF money but once that was in place we were able to successfully advocate for 
the funding for the project. It was very positive in our experience.” 
The effectiveness of CDC staff may be affected by a variety of external challenges. The most 
commonly reported challenges were “Poor Ministry of Health Leadership” (45%), “Length of the 
Process” (42%), “Length of Meetings” (39%), “Lack of Transparency” (35%), “Unclear Communication 
Channels” (34%), and “Poor Quality of Consultants” (30%). One interviewee stated that “missteps and 
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failures regarding GF were ones that all donors shared equally in their engagement with the government,” 
highlighting the importance of coordination and the complexity of arrangements. Numerous other 
challenges were listed by survey respondents; these are captured under Table 14.  
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Table 14: Challenges Faced in Influencing Technical/Strategic Content of Concept Notes 
Response (N=74; multiple 
responses allowed) 
CDC Field Staff 
n (%) 
CDC HQ & Secondee Staff 
n (%) 
All CDC Staff 
n (%) 
Poor MOH leadership 24 (51%) 9 (33%) 33 (45%) 
Length of process 22 (47%) 13 (48%) 31 (42%) 
Length of meetings 18 (38%) 7 (26%) 29 (39%) 
Lack of transparency 18 (38%) 8 (30%) 26 (35%) 
Unclear communication 
channels 
16 (34%) 9 (33%) 25 (34%) 
Poor quality of consultants 13 (28%) 9 (33%) 22 (30%) 
Document management 13 (28%) 7 (26%) 20 (27%) 
Influence of consultants 13 (28%) 6 (22%) 19 (26%) 
Influence of CCM leadership 8 (17%) 6 (22%) 14 (19%) 
Influence of SRs 7 (15%) 2 (7%) 9 (12%) 
Influence of PRs 6 (13%) 2 (7%) 8 (11%) 
Influence of other donors 3 (6%) 3 (11%) 6 (8%) 
Lack of local interest 2 (4%) 4 (15%) 6 (8%) 
Influence of civil society 3 (6%) 1 (4%) 4 (5%) 
Lack of FPMT 2 (4%) 2 (7%) 4 (5%) 
Other 14 (30%) 8 (30%) 22 (30%) 
“Other” included: Not knowing PEPFAR strategy and CDC budget in time; paucity of reliable and current 
program and financial data and reports; lack of one-stop center to provide necessary info; having PEPFAR 
Coordinators at the table instead of technical staff; lack of meaningful engagement with key populations; host 
government not wanting to share with partners, address over/under-funding; lack of commitment and follow-
through by PR and CCM leadership; inability of the government to prioritize and drop PRs; weak CCM secretariat; 
lack of clarity from CDC leadership on how to engage, especially since don’t have dedicated TA funding; not all 
external consultants interested/focused on integrated activities. 
 
Although only 30% of respondents listed the quality of consultants as a challenge in terms of 
influencing Concept Notes, the respondents overall found the quality of the consultants brought in to the 
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process to be suboptimal (Table 15). Only 3% rated them as “Very Good” and 18% as “Good”, with 45% 
rated them as “Average” and 13% rated them “Poor” or “Very Poor”; the distribution was similar between 
field and HQ staff.  
Table 15: Quality of External Consultants Brought In to Develop Concept Notes 
Response (N=77) 
CDC Field Staff 
n (%) 
CDC HQ & Secondee Staff 
n (%) 
All CDC Staff 
n (%) 
Very Good 1 (2%) 1 (4%) 2 (3%) 
Good 10 (20%) 4 (14%) 14 (18%) 
Average 23 (50%) 12 (43%) 35 (45%) 
Poor 4 (8%) 3 (11%) 7 (9%) 
Very Poor 2 (4%) 1 (4%) 3 (4%) 
Don’t Know 9 (18%) 7 (25%) 16 (21%) 
 
When asked to estimate the level of effort directed towards the development of Concept Notes, on 
average respondents reported four CDC staff working at 26% level of effort for four months. The ranges 
were quite broad, with one to 20 staff reported engaged at up to 100% level of effort for up to 10 months, 
as captured in Figure 11. Interviewees described how their level of effort varied depending on the 
presence of a GF Liaison and the timing of the CN with the COP. One said: 
“We’ve had a number of challenges with the CN. For a while, we had a GF liaison in 
country, which was extremely useful. The timing has been hard since the CN process 
started while were doing COP17 and the government relied heavily on our team to pull 
this together. There was no dedicated support from GF or the MOH to pull this CN 
together but there were high expectations on us [CDC].”  
 
Another echoed, saying “Had the CN not happened during COP we would have been even more 
involved. Usually I spent 5%-10% of my time on GF but during February and March, when we were 
doing the CN, it was much, much more.” 
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Figure 11: CDC Level of Effort during Concept Note Development (N=38) 
 
ENGAGEMENT WITH COUNTRY COORDINATING MECHANISM 
Discussion with the Country Coordinating Mechanism was reported as one of the most common 
ways of engaging with GF, especially for field staff (63%). Per Figure 12, among field staff, CDC 
participated in the CCM in various ways, including as a voting member (39%), non-voting member 
(20%), and/or member of a CCM sub-committee (27%). However, the reported rate of CDC having a 
dedicated permanent (21%) or alternate (13%) seat was relatively low, with CDC most commonly (31%) 
rotating into a permanent seat with another USG agency (Figure 13).  
 
 
 
 
 
 
 
 
4
26
40
10
20
30
40
50
60
70
80
90
100
# of CDC staff % level of effort # of months
# 
of
 st
af
f/m
on
th
s o
r %
 o
f e
ff
or
t
High Low Average
41 
 
Figure 12: CDC Role on the CCM (N=55) 
 
Figure 13: Type of CDC Seat on the CCM (N=39) 
 
The official Global Fund 2014 CCM Composition Report13 corroborates the relatively low 
number of dedicated CDC permanent CCM seats, with CDC listed as a member in eight CCMs, out of 
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148 total. While overall USG participation is much higher globally (Figure 14), USAID dominates 
membership, with additional seats held by U.S. Embassy (agency undefined) and the PEPFAR 
Coordination office.  
Figure 14: Official USG CCM Representation
 
CDC only USAID only PEPFAR only U.S. Embassy only 2+ USG agencies 
Countries/regions with CDC representation on the CCM, per GF: China, Kazakhstan, Kyrgyzstan, 
Multicountry Americas, Rwanda, South Sudan, Tanzania, Zimbabwe  
 
Interviewees confirmed that CDC participation on the CCM varied greatly among countries. “I 
think at the country level not all CDC country offices are involved in the CCM at all. In some countries 
they are very involved and focused on getting to know the CCM and if it is a strong body in country and 
who is driving the agenda there; that’s important,” said one. In contrast, others, even those highly 
involved in the development of CNs, were unsure of if and how CDC was participating on the CCM. Said 
an interviewee, “We haven’t done well at engaging the CCM or local GF focal points. Mostly it’s when 
the FPM comes to town. It could just be my level, at the technical level, but I’m not sure who sits on 
CCM. Maybe USAID, representing PEPFAR?” Interestingly, these individuals had worked in the same 
country for CDC, at different times, and were referring to the same CCM.  
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However, in some countries CDC had a formal role on the CCM and worked closely with other 
agencies. As one interviewee explained: 
“Both CDC and USAID made a concerted effort to be engaged in CCM. USAID had a 
big role in the CCM. PEPFAR had a seat on the CCM, USAID had a seat or alternate 
seat, CDC had an alternate role. At any time, all three had a full membership or alternate 
membership on CCM so we had to do a lot coordination. We got pulled into permanent 
committees and ad hoc working groups so all agencies had to be involved, when to pull 
back and let the technical staff step in.” 
 
Some individuals, particularly GF Liaisons, saw “capacitating the CCM” and “sharing 
information on USG programs with the CCM” as major elements of their jobs. “From the CDC side, we 
should be sharing information and our technical skills with the CCM, sharing key documents with in 
country actors and the FPM,” said one. Similarly, another Liaison stated that “We need to provide 
complementary info on what we are doing with PEPFAR. I give updates technical committees of the 
CCM on what PEPFAR is doing and State does the same with the CCM.” 
COORDINATION WITH OTHER STAKEHOLDERS 
When asked which U.S. Government agency serves as the primary focal point for GF activities in 
their context, only one respondent stated that CDC was designated for this purpose (Figure 15). In terms 
of other agencies, 19% reported USAID, 15% reported the Department of State, and 45% reported 
“Other”; most of the responses under “Other” refer to the PEPFAR Coordinator, which is generally under 
of the Department of State. With regard to the presence of full-time staff dedicated to GF activities, 60% 
of respondents reported that no such positions exist in other agencies’ offices in their country, with 
another 24% unsure; only three respondents (7%) reported that the Department of State has such a 
position (Figure 16). Together, these results indicate that most commonly, the responsibility for serving as 
the GF main contact falls to the PEPFAR Coordinator/DOS, although the office is rarely staffed with a 
dedicated staff person for that purpose.  
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Figure 15: USG Agencies Serving as Primary Focal Point for the Global Fund (N=47) 
 
Figure 16: USG Agencies with Staff Dedicated Full Time to Global Fund Activities (N=45) 
 
Beyond the USG, other stakeholders participate in GF activities to various degrees, as shown in 
Figure 17. With the exception of the U.S. Embassy Front Office and certain disease-specific institutions 
(i.e., Roll Back Malaria, KNCV), the level of engagement is extremely high. Unsurprisingly, engagement 
is highest for the Ministry of Health, with 90% rating it “Very High” (77%) or “High” (13%). However, 
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quality for Ministries of Health as “Neutral” (38%) or below (Figure 18). The lowest ratings were for 
UNICEF (65% at “Neutral” or below), other UN agencies (72% at “Neutral” or below), and other 
bilaterals (79% at “Neutral” or below).  
Figure 17: Other Stakeholders’ Level of Involvement in Global Fund Activities (N=61) 
 
Figure 18: Quality of Contributions to Global Fund Activities from Other Stakeholders (N=56) 
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Involvement by host country financial and planning institutions (e.g., Ministry of Finance, 
Ministry of Planning, and Ministry of Treasury) in GF processes is largely during the development of 
Concept Notes (52%) and monitoring and reporting on grants (35%) (Figure 19). Positively, only 12% 
reported that such institutions do not participate in GF activities.  
Figure 19: Engagement of Host Country Financial and Planning Institutions in Global Fund 
Activities (N=55) 
 
CDC staff seem generally well aware of the other stakeholders in GF arena but are primarily 
focused on the MOH. However, they recognized the need to interact with other donors and influencers, 
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“These partnerships are not just either direct financial relationships like a cooperative 
agreement or high level political partnerships—they are in fact technical partnerships and 
each of those partners in this relationship (GF, CDC, WHO) plays a different role in how 
global health decisions are made at global level and country level, even down to the 
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“My role with GF was through the Development Partners for Health group, which is one 
of the bodies that meets with GF and that GF gives updates. It was important to make 
sure that all donors in this space share information, to have clear objectives, and to not be 
tasked to do the same work. When I started, I found that there was a lack of info sharing 
between donors. It was important for me to learn more about GF so I could speak 
intelligently in their terms about what PEPFAR is supporting and what other countries 
are contributing in terms of donor support.”  
EXTERNAL AND INTERNAL COMMUNICATION 
In order for CDC staff to be most effective in their collaboration with GF, strong communication 
and coordination structures are critical, both externally with the Fund Portfolio Management Team 
(FPMT) and internally between CDC HQ and field staff. With regard to the first element, phone calls 
with the FPMT seem to be largely ad hoc (52%) or never (29%) (Table 16). The case seems to be similar 
for in-person meetings, with 53% reporting only ad hoc meetings and 26% reporting never meeting with 
the FPMT (Table 17). For both modes, field staff report higher rates of ad hoc meetings and HQ staff 
higher rates of never communicating/meeting with the FPMT.  
Table 16: Frequency of Phone Calls with Fund Portfolio Management Team  
Response (N=62) 
CDC Field Staff 
n (%) 
CDC HQ & Secondee Staff 
n (%) 
All CDC Staff 
n (%) 
Weekly or every other week 2 (5%) 2 (10%) 4 (6%) 
Monthly 1 (2%) 1 (5%) 2 (3%) 
Every other month 5 (12%) 1 (5%) 6 (10%) 
On an ad hoc basis 25 (61%) 7 (33%) 32 (52%) 
Never 9 (20%) 10 (48%) 18 (29%) 
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Table 17: Frequency of In Person Meetings with Fund Portfolio Management Team  
Response (N=62) 
CDC Field Staff 
n (%) 
CDC HQ & Secondee Staff 
n (%) 
All CDC Staff 
n (%) 
Weekly or every other 
week 
1 (2%) 1 (5%) 2 (3%) 
Monthly 1 (2%) 0 (0%) 1 (2%) 
Every other month 8 (19%) 2 (10%) 10 (16%) 
On an ad hoc basis 27 (64%) 6 (30%) 33 (53%) 
Never 5 (12%) 11 (55%) 16 (26%) 
 
The most commonly reported challenges affecting communication between CDC staff and the 
FPMT were CDC not being included in exchanges (29%), a lack of a point of contact to initiate dialogue 
(25%), and turnover within the FPMT (23%) (Table 18). 
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Table 18: Challenges Faced in Terms of Communicating with the Fund Portfolio Management 
Team 
Response (N=52; multiple 
responses allowed) 
CDC Field Staff 
n (%) 
CDC HQ & Secondee Staff 
n (%) 
All CDC 
Staff n (%) 
Not included in 
communication with FPMT 
10 (29%) 5 (29%) 15 (29%) 
No POC to initiate 
communication 
9 (26%) 7 (41%) 16 (25%) 
Turnover within FPMT 10 (29%) 2 (12%) 12 (23%) 
Lack of time for calls 8 (23%) 1 (6%) 9 (17%) 
Differences in policy 
priorities 
5 (14%) 4 (24%) 9 (17%) 
Differences in technical 
priorities 
5 (14%) 3 (18%) 8 (15%) 
Lack of FPMT interest 2 (6%) 3 (18%) 5 (10%) 
FPMT does not visit 
country 
2 (6%) 2 (12%) 4 (8%) 
Other 9 (26%) 6 (35%) 15 (29%) 
 
However, CDC field staff have made efforts to proactively share information with the FPMT, as 
appropriate. The majority reported frequently or sometimes sharing official plans once cleared (78%), 
other unofficial news or contextual updates from the country (69%), updates on program implementation 
(68%), unofficial updates from the CCM, PRs, or SRs (57%), or official plans in draft form (51%) (Figure 
20). Members of the FPMT were also the most likely to be scheduled to attend the COP regional review 
meetings for those CDC countries implementing PEPFAR, with 35% reporting planned FPMT 
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participation (Figure 21). An additional 15% reported expected CCM participation and 12% PR or SR 
attendance.  
Figure 20: CDC Field Staff Proactive Sharing of Information with the FPMT (N=45) 
 
Figure 21: Global Fund Participation in COP Review Meetings (N=38) 
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Interviewees were consistent in their belief that CDC direct engagement with the FPMT was vital 
and could be mutually beneficial. Said one, “I got a crash course [in GF] by starting a good relationship 
with our FPM. We had regular, frequent calls and in person meetings. We became resources to each other 
because the COP process and other USG politics came up. I was able to provide insights and background 
on what was going on. We were able to teach one another and make sure we were up to speed.” However, 
they also detailed some of the challenges with building that relationship, explaining that: 
“I frequently heard, ‘Well, I’m not on the CCM so I can’t meet with the FPM’ but there is 
absolutely no reason that CDC staff cannot meet with the FPM. We need to know those 
people, nurture those relationships and share info. It’s very valuable to CDC in terms of 
our own processes—we get great feedback on our MOP, COP, and TB work, their input 
can be fantastic—and there are cost efficiencies in their program that we need to look at.”  
 
Similarly, another stated that, “Our FPM is helpful and cordial but it is hard to build a 
relationship because she is not here all the time—we can’t consistently engage. The FPMT did try to 
participate at every stage of the CN. There is a good faith effort but it’s hard because they are not in 
country.” From these examples it is clear that there is a desire for more coordination with the FPMT, but 
structural issues—both real and perceived—may be inhibiting CDC staff from doing so. 
In terms of CDC internal communication, low levels of exchange were reported between CDC 
HQ and field staff on GF issues. Over 65% of HQ staff and 51% of field staff reported being in contact on 
GF matters only once or twice a year, with an additional 8% of HQ staff and 25% of field staff stating that 
they are never in touch with each other on such issues (Figure 22). This situation may be due in part to a 
lack of official points of contact at HQ on GF issues or updates, as only 15% of field staff reporting 
having such a contact (Figure 23). Almost half (48%) reported not having such an official contact nor 
reaching out unofficially to any HQ staff on regarding GF. 
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Figure 22: Frequency of Communication between CDC HQ & Field Staff on Global Fund (N=90) 
 
Figure 23: CDC Field Staff Reporting a HQ Official Point of Contact for Global Fund (N=54) 
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a group of people, as it’s not very clear.” Others were more blunt, stating, “I wouldn’t know who to turn 
to. My experience has been that CDC left it to country to figure things out,” and “No, I didn’t feel like 
there was anyone I could reach out to. But I didn’t need anyone from CDC to help me do my job because 
no one knew more than me. I wish I could say there was someone I could have reached out to but there 
was no one who knew enough to assist me.” Another interview raised the issue of strategic alignment 
with in the agency, explaining:  
“There is a disconnect at CDC between the people who engage with GF and those who 
do at the field level so improving our internal flow of information would be helpful. It’s 
not clear in Atlanta beyond technical people who is working with the Fund and what they 
are working on. There is no policy link between those who are conducting technical 
reviews or other high level work and those of us in the field. We don’t know how strategy 
trickles down to the field and how we make sure that our positions are the same on both 
ends. CDC could do this much better.” 
 
In contrast, several interviewees highlighted that the Office of the Global AIDS Coordinator 
(OGAC) in the Department of State has occasionally served as a resource for them, especially those 
serving as GF Liaison. They said:  
“The multilateral office at OGAC started to do monthly calls that CDC staff were invited 
to attend. Those were opportunities to share documents, and have conversations about 
strategy and what was coming out of Board meetings. We got information that we 
couldn’t get from other sources. It was a forum for liaisons could talk through issues. 
When HQ support became really important was as the NFM and CN process rolled out. 
They helped us get tools and documents just a little bit earlier—that brought me a lot of 
credibility in country, as I was familiar with the material when it was broadly released.” 
 
“I haven’t dealt with CDC HQ regarding GF. Mostly what I get from CDC is from all 
hands meetings on technical issues, including on GF. But from OGAC office we get 
emails on GF meetings, key decisions, input on GF strategy. We have monthly calls to 
exchange info and get presentations to build our skills and capacities. They have a focal 
person at OGAC who helps us.” 
  
STAFFING AND KNOWLEDGE 
The Concept Note development process was reported as being the most common forms of CDC 
engagement with GF, as well as one of the most time-consuming. But beyond the Concept Note, CDC 
staff devote significant effort to GF activities, with 43% of field staff and 29% of HQ staff spending 5%-
25% of their time on such issues; an additional 14% and 10% spent more than 25% of their time on GF 
(Table 19). Given the number of competing demands facing CDC staff, this percentage is quite sizeable, 
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especially when considering that the vast majority of respondents (93%) stated that their office does not 
have staff dedicated full time to GF activities (Figure 24). One interviewee articulately made the case for 
a GF liaison, raising issues of time, effort, and knowledge: 
“As largest donors and implementers in country, there is a natural marriage of GF and 
USG; we should be on the same page. It doesn’t require advocacy to come to 
philosophical agreement about where everyone should move but the greater challenge has 
been around mutual awareness and communication. GF processes change constantly, as 
do USG’s, so that means that we need staff who can step away from COP deadline or 
other major USG deadlines and just pay attention to GF —that’s why you need a liaison 
or dedicated point of contact.” 
 
As another explained, “You need dedicated staff to be available to provide the level of support 
that GF needs if you want to do an optimal job. There must be someone having the open conversations in 
the off cycle, dealing with implementation challenges, and getting folks on the same page when the CN 
process comes around.”  
 
Table 19: Time Spent on Global Fund Activities Apart from CN Development  
 
 
 
 
 
 
 
Response (N=80) 
CDC Field Staff 
n (%) 
CDC HQ & Secondee Staff 
n (%) 
All CDC Staff 
n (%) 
More than 50% 1 (2%) 2 (7%) 3 (4%) 
25%-50% 6 (12%) 1 (3%) 7 (9%) 
5%-25% 21 (43%) 9 (29%) 30 (38%) 
0%-5% 21 (43%) 19 (61%) 40 (50%) 
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Figure 24: Offices with CDC Staff Dedicated Full Time to Global Fund Activities (N=75) 
 
CDC staff report that despite their significant involvement in GF, they have rarely received 
formal training on the institution or its processes (Table 20). The majority of field staff (63%) and HQ 
staff (53%) state that they have never received such training. When training has been provided, it has 
been most frequently done by GF itself (17%), USAID or Department of State (10%), or an external 
organization (9%); only 5% reported receiving training from CDC HQ and no one identified the country 
office as their trainer. The lack of formal training seems to persist, as 40% of staff say that they do not 
currently receive updates on GF policy, strategy, or processes (Table 21). Those who do get them from 
the Fund Portfolio Manager or other GF staff (39%), an email, call, or newsletter from CDC HQ (18%), 
Global Fund News Flash (14%), or Global Fund Observer newsletter (12%).  
Interviewees most commonly stated that they learned about GF “on the job” or “by doing my 
work.” A few, namely GF Liaisons, mentioned speaking with key contacts in Atlanta and D.C. and 
participating in a one-week training organized by OGAC on multilaterals in 2015. Some interviewees 
have taken online GF trainings but found them “focused internally on how things work in Geneva.” The 
issue of understanding overall strategy and politics came up several times, with one saying that we “Need 
more policy acumen to engage with GF. We [CDC] can’t spend our time engaging just bashing GF —we 
need strategies for supporting what they do.” Another respondent elaborated: “GF processes are slow and 
0
10
20
30
40
50
60
70
80
Yes No
# 
of
 R
es
po
nd
en
ts
CDC Field Staff CDC HQ Staff All CDC Staff
56 
 
frustrating so it takes a lot of time to build relationships, learn who the players are, who is driving 
decisions on the CCM, how effective the Executive Secretariat is, how can we make sure that they 
understand what CDC/USG is doing, what the health portfolio is, and how to collaborate.” They went on 
to describe a proposed continuum of learning about GF: 
“The first step to understanding GF, even before the processes, is getting to know 
the POCs in Geneva, helping understanding what they want and need, what their 
pain points are and how PEPFAR can address those. Once that’s done, we have 
to get to know people in country and demonstrate our value there, showing up for 
the meetings even if they are all day, learning how the decision-making process 
works, the unique aspects of the country. From there we can start understanding 
the nuts and bolts of GF processes, rather than starting with the details of how the 
grant requests get put together and how they are doing monitoring. All of those 
pieces, while they are important, can in isolation inhibit being a real expert on 
GF. Also, you have to really know the portfolio, read through in incredible detail 
what’s in the grants and map it against what CDC is doing. That really helps 
illustrate those areas that are ripe for better collaboration.” 
 
Another respondent highlighted the need not just for a CDC-focused review of GF, but for a 
USG-wide approach, saying: 
 “One of things we push for in here is to provide training on GF from a CDC perspective 
but also an interagency perspective so that everyone who is in the USG space is fully 
versed on GF. That way we can operate as an interagency team and not as individual 
agencies, secretly working to secure GF resources together.”  
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Table 20: Ever Received Formal Training or Briefing on Global Fund Processes  
Response (N=79) 
CDC Field Staff 
n (%) 
CDC HQ & Secondee Staff 
n (%) 
All CDC Staff 
n (%) 
Yes, from CDC HQ 2 (4%) 2 (7%) 4 (5%) 
Yes, from CDC Country 
Office 
0 (0%) 0 (0%) 0 (0%) 
Yes, from Global Fund 8 (16%) 5 (17%) 13 (17%) 
Yes, from USAID or State 3 (6%) 5 (17%) 8 (10%) 
Yes, from external 
organization 
5 (10%) 2 (7%) 7 (9%) 
No 31 (63%) 16 (53%) 47 (60%) 
Other 6 (11%) 5 (17%) 11 (5%) 
Other includes: PMI and RBM; GF portfolio manager at CCM meetings; USAID contractor; self-
orientation using GF website  
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Table 21: Current Method for Receiving Updates on Global Fund Policy, Strategy, or Processes 
Response (N=78; multiple 
responses allowed) 
CDC Field Staff 
n (%) 
CDC HQ & Secondee Staff 
n (%) 
All CDC Staff 
n (%) 
Do not currently receive 
updates 
17 (35%) 14 (47%) 31 (40%) 
Email or call from FPM or 
Global Fund staff 
24 (50%) 6 (20%) 30 (39%) 
Email, call, or newsletter 
from CDC HQ 
7 (15%) 7 (23%) 14 (18%) 
Global Fund News Flash 5 (10%) 6 (20%) 11 (14%) 
Global Fund Observer 
newsletter 
4 (8%) 5 (17% 9 (12%) 
Other 8 (17%) 6 (20%) 14 (18%) 
Other includes: Global Fund website; informal discussion with CCM; PEPFAR Coordinator; WHO 
colleagues, via email; Implementing partners; OGAC multilateral team; Emails or calls from USAID 
HQ; GF Liaison; USAID; PAHO; PEPFAR Technical Working Group 
 
The lack of formal training and updates may contribute to the overall low level of (self-reported) 
knowledge of GF approaches and processes (Figure 25). For all seven domains queried, over 60% of 
CDC staff rated their knowledge as “Average” to “Very Low,” with the largest reported knowledge gaps 
for HQ and field staff in decision-making (78%), grant-making (78%), and governance (76%). 
Knowledge among field staff was highest for Concept Note development, although only 44% rated their 
knowledge as “High” or “Very High”; HQ staff were strongest with regard to GF strategy and objectives, 
with 30% rating their knowledge “High” or “Very High”.  
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Figure 25: Self-Reported Level of Knowledge of Global Fund Approaches and Processes (N=78) 
 
Positively, CDC staff are extremely interested in learning more about GF, with at least 59% 
stating that they are “Quite Interested” or “Extremely Interested” in all seven domains (Figure 26). 
Monitoring and evaluation (76%), strategy and objectives (70%), and decision-making (70%) were of 
highest interest overall, including for field staff (84%, 75%, and 75% respectively). HQ staff were most 
focused on monitoring and evaluation (66%), strategy and objectives (63%), decision-making (63%), and 
implementation (63%). Desire was 11%-18% higher among field staff compared to HQ staff in all areas 
except for implementation (4% higher) and governance (1% lower).  
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Figure 26: Level of Interest in Learning More about Global Fund Approaches & Processes (N=77) 
 
FUTURE CDC TECHNICAL ASSISTANCE 
Given the high level of CDC engagement with GF and deep technical expertise of the agency, 
CDC is well-placed to provide technical assistance to the institution on a wide range of issues. The vast 
majority of respondents state that CDC should provide technical assistance on numerous issues, 
particularly epidemiologic analysis and target-setting (91%), laboratory systems planning (84%), disease-
specific programs (79%), and strategic planning (75%); six other domains were supported by at least 60% 
of respondents (Table 22). In terms of how such technical assistance should be delivered, the preferred 
method of both HQ and field staff was via CDC staff placed in country offices, followed by CDC staff 
seconded to GF PR(s) (Table 23). 
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Table 22: Topics/Activities CDC Should Provide Technical Assistance on to Global Fund 
Response (N=79; multiple 
responses allowed) 
CDC Field Staff 
n (%) 
CDC HQ & Secondee 
Staff 
n (%) 
All CDC Staff 
n (%) 
Epi analysis, target-
setting 
45 (94%) 27 (87%) 72 (91%) 
Lab systems planning 44 (92%) 22 (71%) 66 (84%) 
Disease-specific programs 38 (80%) 24 (77%) 62 (79%) 
Strategic planning 37 (77%) 22 (71%) 59 (75%) 
Program M&E 31 (65%) 25 (81%) 56 (71%) 
QI systems 35 (73%) 20 (65%) 55 (70%) 
Gaps analysis 34 (71%) 19 (61%) 53 (67%) 
Proposal development 30 (63%) 22 (71%) 52 (66%) 
Program planning 31 (65%) 199 (61%) 50 (63%) 
Program implementation 27 (56%) 19 (61%) 46 (58%) 
Financial analysis 16 (33%) 11 (36%) 27 (34%) 
Other 4 (8%) 3 (10%) 7 (9%) 
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Table 23: Preferred Method for Provision of Additional Technical Assistance to Global Fund 
Preferred Method for Provision of Additional Technical Assistance to Global Fund 
Response (N=78) 
CDC Field Staff 
Ranked Score 
CDC HQ & Secondee Staff 
Ranked Score 
All CDC Staff 
Ranked Score 
CDC staff in country 
office 
5.08 5.33 5.18 
CDC staff seconded to PR 5.00 4.87 4.95 
CDC HQ technical staff 3.60 3.97 3.74 
Multilateral institutions 3.44 3.47 3.45 
NGO partners 2.50 2.07 2.33 
Other 1.38 1.30 1.35 
 
Feedback from interviewees was consistent with the survey results. Data and analysis was a 
major theme, with one interviewing asserting that “we should share site level data, that rich granular data 
we have to help GF with the risk assurance to build out their performance indicators. CDC should really 
be looking at that piece more closely.” Another echoed this point, saying: 
“In terms of support, being more engaged technically at country level and doing more 
data level as the Fund’s model evolves in whatever direction. Making sure they have 
access to our data, all of it, from expenditure analysis to unit price for packages, all of 
that is very valuable and will help GF as they think about their comparative advantage as 
a financing mechanism as compared to in country technical partner.” 
 
 Interviewees were clear that this was primarily the responsibility of the in-county team but that 
HQ technical advisors would be critical in helping conduct the analysis and educating GF HQ on the 
findings. Said one: 
“We need someone, in a detailed way, walking the FPM through our analysis process. 
Like, ‘here’s our strategy, here’s a map of where our focus is, here’s what our investment 
is, here are the cadres we are supporting, here are the health information systems we have 
invested in.’ All of that nitty gritty that CDC has technical expertise in needs to be 
shared.” 
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BEST PRACTICES AND RECOMMENDATIONS 
The survey asked respondents to identify current best practices and offer recommendations to 
improve CDC operations regarding GF in three domains. The major themes and most common responses 
are summarized below. 
ENGAGEMENT AND TECHNICAL ASSISTANCE 
Both the high quantity and quality of CDC engagement with GF were emphasized as best 
practices, with several statements about engaging “early and often” and ensuring that CDC was part of 
epidemiologic, gap, and program analyses. Being ready to provide high quality technical assistance is 
imperative, especially in CDC core areas such as laboratory systems, key populations, health information 
systems, and monitoring and evaluation. Respondents stated that when CDC was not engaged in the 
development of the Concept Note and supporting materials (e.g., epidemiologic analysis, data quality 
assessment, study of treatment outcomes), the quality of outputs was suboptimal and their utility 
decreased. Reducing the influence of external consultants and requesting direct technical assistance from 
CDC had resulted in stronger products (including Concept Notes) in other contexts and was considered a 
best practice. CDC direct assistance was cited as having saved some country programs from losing their 
grants, preventing large gaps in availability of essential commodities, and/or shifting portfolios to more 
evidence-based interventions.  
Technical and leadership staff within CDC were encouraged by respondents to increase the 
frequency and volume of engagement with management of GF. Institutionalizing processes (e.g., monthly 
calls between CDC and FPMT, in person meetings during every FPMT mission to the country) was seen 
as important, so that continuity in the relationship would not be affected by turnover on either side. 
Establishing a connection with the FPMT early in a CDC Country Director’s tenure was considered 
imperative, as were short, frequent updates via phone or email; both actions were reported to have helped 
resolve long-pending Management Actions and outstanding technical issues.  
Decreasing duplication, promoting complementarity, and ensuring equity in service packages 
supported by CDC and GF was a high priority for respondents. Concerns about parallel M&E systems, 
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the lack of harmonized USG and GF targets, and overall technical guidance were common, but 
respondents often stated that that these needed to be resolved at the HQ level. Similarly, some 
respondents wanted CDC leadership to encourage GF resources to be directed primarily at procurement of 
commodities, rather than for interventions/services, as those were considered the most susceptible to 
being influenced by local politics and external consultants, rather than scientific evidence.  
With many countries facing decreasing support from USG/CDC, the issues of transition and 
coverage of gaps were raised several times. Stronger communication was desired between USG/CDC, 
GF, and the Ministry of Health to promote transparency on impending gaps, establishment of monitoring 
plans, and identification of alternative funding sources to prevent disruption of essential services.  
With regard to CCM representation, numerous respondents stated that CDC was hampered by the 
lack of a dedicated, permanent seat. This was particularly true for countries where i) CDC is the 
predominant implementing agency of health programs (but where other agencies may have a seat), ii) 
there is significant overlap between the activities supported by CDC and GF, and iii) CDC and GF share 
recipient partners. Almost universally, respondents wanted CDC to have its own seat on the CDC, 
alongside (rather than instead of) other USG agencies. Participation within CCM subcommittees and 
working groups, and direct support of the CCM Secretariat, were also cited as areas for enhanced activity.  
With regard to implementation, joint site visits (both with and without respective HQ leadership) were 
recommended to become more frequent, along with reviews of program data. For the latter, respondents 
encouraged integration of GF results into required USG data systems and reviews to guarantee 
participation, transparency, and harmonization. Finally, CDC HQ and field engagement on both mock and 
real Technical Review Panels was also considered a vital next step and one that would greatly increase 
the quality and relevance of the reviews. 
CDC STAFFING, SKILLS, AND KNOWLEDGE 
Interagency GF Liaison positions were considered essential by most respondents, with specific 
benefits provided by Liaisons including providing weekly updates on GF activities, serving as a triage 
point for multiple requests, handling complex governance and management issues, and educating 
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agencies on GF processes. As one interviewee described it, “CDC Country Directors should ensure that 
senior staff are engaged with GF and bring in the Liaison to talk about GF structures or facilitate 
conversations about implementation and process.” In addition to Liaisons, almost all respondent strongly 
advocated for CDC-specific staff dedicated to multilateral engagement; these technical positions would be 
focused on data analysis, program prioritization, operational planning, and Concept Note development, 
going beyond the standard focus on governance and process issues of Liaisons. A few individuals 
suggested that these positions be based at the CCM, Secretariat, or Principal Recipients, but most thought 
it would be more efficient to have them housed within the CDC office.  
A best practice was for position descriptions to clearly state expectations regarding level of effort 
on GF activities and encourage leadership on GF issues. Where an additional CDC position dedicated to 
addressing GF was not possible, respondents recommended designating an existing senior position as the 
primary point of contact and providing the incumbent training on GF processes and systems. The 
individual would need to be able to convey information between CDC, the CCM, Principal Recipients, 
the FPMT, the host government, other USG agencies, and other stakeholders, as well as be able to make 
technical and strategic recommendations. He/she would also “put together briefing packages for the FPM 
so they can really understand what’s going on, especially from the CDC side,” as one interviewee put it.  
In terms of a best practice, several individuals stated that when colleagues with knowledge and 
skills related GF gave presentations to their teams, the information was very warmly received and put to 
use. Respondents wanted encouragement of this peer-to-peer learning and integration of GF topics into 
routine team meetings, retreats, and trainings, including at the major CGH Annual Meeting.  
Respondents strongly supported formal training for CDC staff on GF, particularly for Country 
Directors and senior technical advisors. The ultimate goal is to guarantee that all relevant staff 
(particularly those working on PEPFAR, PMI, and TB Care 2.0) have a working knowledge of GF. The 
training was recommended to be provided early in an employee’s time with CDC and could be conducted 
jointly with HHS, OGAC, or USAID. An orientation visit to GF HQ for Country Directors was 
considered a good investment, as it would improve understanding of the operational environment, 
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priorities, and processes. As an interviewee said, “Country Director need to be well-informed when 
voting on issues in the CCM to move the country ahead. To do that, they need to know the full GF 
landscape.” 
For CDC HQ, recommendations included continuing secondee positions to GF in Geneva and 
establishing a multilateral team within CGH. In addition, respondents proposed creating a CDC— GF 
Technical Working Group across Divisions to increase CDC’s visibility and ability to discuss specific 
policy and technical issues. The group could conduct joint supervisory site visits to countries, exchanges 
between Atlanta/D.C. and Geneva, and participation on reviews of USG plans (e.g., COP, MOP) and GF 
Concept Notes.  
In addition, respondents suggested the designation of a HQ point of contact for GF Liaisons or a 
partner support team for GF matters with CGH. These would provide pro-active updates on GF 
developments to the field and across CDC CIOs, along with providing general problem-solving and 
communications support. “It would be very advantageous to CDC, especially CGH, to have a person or 
resource who is well versed in GF who could provide consultation and technical support when needed,” 
said an interviewee. “I think that our division and CDC as a whole could do better in communicating if 
there is a POC for our engagement with GF, especially we don’t communicate well what we’re doing in 
support of GF. Having someone at the CGH level would help,” said another.  
Training for CDC Country Officers on the requirements for Concept Note development, potential 
technical assistance opportunities for CDC HQ, and best practices (both in terms of technical content and 
methods of coordination) was also suggested. A document enumerating expectations for Country Officers 
and standards for engaging was desired, as Country Officers were unsure of their particular role in 
assisting with resolution of GF activities or the strains placed on country teams during Concept Note 
development.  
COMMUNICATION AND COORDINATION WITH STAKEHOLDERS 
In terms of communication with the FPMT and other GF staff, CDC respondents stated that it 
was vital to continue to proactively offer information to the FPMT, including on annual plans and 
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programs (both those receiving funding and those being discontinued), technical and geographic priority 
areas, and funding levels (particularly to shared Principal and Sub-Recipients. As one interviewee said, 
“Everyone needs to understand the priorities up front. Knowing the expectations and what the respective 
guidance is for each program is crucial.” 
To improve communication between CDC country and HQ offices, respondents proposed 
development of a CDC strategy on engagement with GF that would guide and standardize activity in the 
field. As one interviewee argued, “We should have a team who can provide resources to countries and 
provide a higher level strategic vision of how we should be engaging with GF, rather than being left 
entirely to do it on our own. Even an informational packet or a CDC guide to how we engage with GF, 
perhaps even a strategy document that could be shared would help tremendously.” 
They also suggested a monthly update on GF issues from HQ to interested parties in the field and 
at HQ that would include both best practices and lessons learned from the field (and HQ technical 
assistance providers) as well as news on GF policy changes. Within HQ, technical and strategic meetings 
and exchanges were encouraged between teams supporting GF activities to discuss shared experiences, 
lessons learned, and opportunities for future collaboration. One interview felt strongly about this, stating: 
“We don’t document well in an internally public space what we’re doing with GF. Maybe 
this is something that can be done at the CGH level, sharing info on how we are 
coordinating activities because it varies by disease area or country. We should have a 
more standard approach to how we engage and define our role in that global health space 
to differentiate CDC from other partners. Our partnership with GF is a strategic one. It’s 
not the same as a partnership with an implementing partner or a MOH or USAID even—
it’s beyond that and it’s important that we build or use our core competencies, to put 
those on the table and define our role more clearly for our engagement with GF.” 
 
In terms of external stakeholders, respondents recommending identifying key stakeholders with 
similar values and cultivating them as early as possible in key activities, such as Concept Note 
development. Sensitizing these stakeholders to a data-driven approach and updating them on the latest 
evidence-based programs was considered essential. Where the Ministry of Health is a Principal Recipient 
as well as a CDC cooperative agreement partner, CDC should work closely with the relevant management 
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units of the Ministry to align administrative and technical priorities, discuss distribution of staffing 
support, and hold joint reviews of financial and program progress.  
SUMMARY OF FINDINGS 
Overall, this study found that there is a high degree of interest among CDC staff in GF and that 
engagement with GF is considered very important to their work but that CDC is not necessarily 
maximally effective in its collaboration. CDC staff face multiple challenges regarding GF, including lack 
of formal roles and responsibilities, low levels of self-reported knowledge, deficiencies in training, 
unclear support and communication systems, and deficiency in dedicated staff or time for engagement. 
There is a desire for more strategic direction, training, and prioritization of GF collaboration, particularly 
among country-based staff.  
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CHAPTER 5: PLAN FOR CHANGE 
PRIORITY RECOMMENDATIONS 
CDC staff, particularly those in country, are deeply engaged with the development and 
implementation of GF activities and recognize the importance of this work. However, there remains 
significant opportunity to improve the impact of this engagement and in turn, the effectiveness of GF 
investments. This analysis yielded numerous suggestions and recommendations to improve collaboration, 
but the majority centered on a few key proposals to address major bottlenecks. In order to address the 
most pressing challenges, my advocacy within CDC will focus on the four major recommendations that 
emerged from the survey and interviews. Namely: 
1. CDC should support the hiring of additional GF Liaisons in-country and the establishment of a CGH-
level GF or Multilateral Affairs team.  
2. CDC should work with GF leadership to encourage CCMs to include a dedicated seat for the agency 
and/or to promote rotation of USG seats among agencies. This would enable greater direct 
involvement of CDC staff in GF activities and may result in less reliance on external consultants.  
3. CDC should identify and systematically promote training opportunities on GF processes, systems, 
and priorities, in particular among field staff. These may include existing virtual trainings (from the 
GF website, partner webinars), live seminars and informational sessions (at meetings and using HQ 
liaison and seconded staff), and applied learning opportunities such as participation in mock or actual 
Technical Review Panels. 
4. CDC should seek additional financial resources which would enable expansion of field-based TA in 
support of GF processes and programs. This should include both in-house and seconded cross-cutting 
subject matter experts who can support HIV, TB, malaria, and health systems strengthening grants 
and programs, as appropriate. These TA staff should be focused on high impact GF countries which 
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are also countries with substantial USG financial resources or strategic importance. These additional 
TA staff would utilize established Ministry of Health relationships and operational knowledge, 
including via cooperative agreements, to augment the quality of in-country technical support and 
capacity. Ancillary benefits would be to reduce the reliance on external consultants of suspect quality 
and the amount of time required by other technical staff already facing demanding workloads. 
OPPORTUNITIES FOR AFFECTING CHANGE 
In my current role as the Associate Director for Policy for the Division of Global Health 
Protection and an experienced CDC country office staffer, I am in a position to influence CDC’s 
strategies towards external engagement, including with GF. Through participation on various policy 
working groups and discussions with senior leadership, I may be able to bring to the forefront the current 
challenges with the GF partnership and share recommendations for addressing them. Collecting and 
analyzing the data presented here may serve as a catalyst for reforming and strengthening CDC’s 
engagement with GF, and may be well-timed given changes in leadership at both institutions. I will also 
be leading the development of my Division’s partnership strategy and will be able to incorporate lessons 
learned and best practices from this research.  
In order to ensure utilization of this information by CDC, I will follow Kotter’s Eight Step Model 
for Leading Change, which is described in Figure 27 below. Each step will be undertaken as part of 
concerted, strategic effort. Before moving to the next stage, I will assess progress, document lessons 
learned, keep track of stakeholders’ responses, and develop effective communication strategies and tools 
that integrate feedback from others’.  
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Figure 27: Kotter’s Eight Step Model for Leading Change 
 
From “Leading Change: Why Transformation Efforts Fail.” John P. Kotter, Harvard Business Review, 
January 2007.  
 
STEP 1: CREATE A SENSE OF URGENCY  
 Once the analysis and recommendations documented here are refined and prepared for 
dissemination within CDC, I will arrange informal meetings with key actors on partnerships within the 
agency. This will include those who work on multilateral affairs, policy development, resource 
mobilization, country support, and leadership development at the Division, Center, and possibly Office of 
the Director levels. During these meetings I will share the most critical findings from this research, 
highlighting that CDC are highly involved in GF and recognize the importance of doing so, but also are 
frustrated by their lack of impact and effectiveness. This will speak to CDC’s interest in improving staff 
72 
 
morale and promoting efficiency, especially at this time of declining or flat funding for global health. I 
will stress that the current situation is untenable and will only be exacerbated by the potential roll-out of a 
new operational approach by GF and/or priorities by USG. I will frame the ongoing leadership and 
strategic changes at GF and CDC as a major opportunity, stressing that is a unique moment for both 
agencies and that such leadership turnover will likely not occur for another four years. Their input will be 
sought on potential champions for reform at all levels of the agency, effective arguments to make with 
each, and timing for approaching each new champion.  
STEP 2: BUILD A GUIDING COALITION  
Building on the guidance from those consulted in step 1, I will reach out to potential, well-placed 
champions to help advance this cause. The goal will get these individuals to recognize the opportunity for 
reform, understand the key issues, and feel passionately about prioritizing this work within their portfolio. 
I will highlight the issues and openings more relevant to them, tailoring my arguments for each while not 
losing the overall messages and cross-cutting objectives. Once they are on board, I will introduce them to 
each other and the key stakeholders from step 1, helping to solidify the individuals into a single working 
group. Depending on size, focus, and placement/role within CDC, it may be necessary to form smaller 
sub-groups. For example, those more distal from direct GF technical engagement, such as individuals 
from the Office of the Director, may want to concentrate solely on Geneva- or D.C.- level issues.  
STEP 3: FORM A STRATEGIC VISION 
 As a collective, we will define our shared goals, which will likely be to encourage leaders to 
adopt of our recommendations and allocate resources (both human and financial) needed for 
implementation. Our vision statement will reflect our joint commitment to advancing a more impactful, 
strategic collaboration with GF at HQ and field levels through a variety of approaches. We will also 
sketch out strategies to implement this vision, including how to communicate with leadership, how to 
ensure buy-in from those who will need to modify behavior or change their roles, and how to message 
outwardly to GF and other stakeholders.  
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STEP 4: ENLIST A VOLUNTEER ARMY & COMMUNICATE THE VISION 
 The coalition will share this vision to leadership via a coordinated, well-timed roll-out. It will 
begin with presentations to existing working groups, such as the CGH and Division Policy Team. Their 
feedback and suggestions will be incorporated into the next iteration of the presentation to leadership at 
the Center and Office of the Director levels. At those sessions we will emphasize the technical and 
management benefits of reform for both HQ and country staff, and detail the action plan for 
implementation and coordination with GF management.  
To communicate beyond leadership, we will advocate for the inclusion of these recommendations 
at the CGH Annual Meeting and for the recommended actions to be presented at that time. It should also 
be discussed on global calls, such as with the Country Directors, Deputy Directors, Locally Employed 
Staff Advisory Group, and topic-specific Technical Working Groups.  
For those unable to join in-person meetings or calls, we will prepare a two-pager with visuals 
explaining the current situation and challenges, proposed solutions and justifications, and opportunities 
for their engagement. This outreach will discuss not only the benefits of reform for CDC but also for GF, 
local Ministries of Health, implementing partners, and other stakeholders.  
STEP 5: ENABLE ACTION BY REMOVING BARRIERS 
 During the presentations and meetings, we will underscore how passionately CDC staff feel about 
these issues, the frustration and inefficiency in the existing approach, and best practices from those who 
have found ways to address challenges. We will encourage others to document and share other strategies 
for improving GF collaboration and brainstorm with them alternative actions that can be taken 
immediately. If feasible, we will bring in experts from the field, particularly GF Liaisons, who can answer 
specific questions or provide testimonials on current barriers and lessons learned. We may connect 
innovators in this field to others who want to pilot our recommendations, or participate in training of new 
staff so they bring fresh ideas to their postings.  
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STEP 6: GENERATE SHORT-TERM WINS 
 To demonstrate proof of concept for these ideas, we will establish an ad hoc GF engagement 
working group, until a formal one is approved by leadership. In addition to serving as a technical 
assistance provider, the group will work to highlight effective GF engagements in CDC communication 
materials. For example, in Division and CGH newsletters we will showcase the impact of CDC country 
teams which have a seat on the CCM and ask them for suggestions about how other CDC offices can 
successfully advocate for their own seat. We will offer to strategize with teams about how to gain a seat, 
particularly if their CCM is undergoing restructuring.  
For countries willing to push for a GF Liaison, we will assist with developing the scope of work 
and moving it through the approval process, as well as with recruitment and selection once the job 
announcement comes out. As another short-term win, during CDC award cycles, we will put forward 
nominations for individuals and teams which have adopted recommendations, best practices, and 
innovations in GF collaboration as incentive for others to do so. Finally, we will seek out ways to 
integrate GF into trainings for HQ and field staff, such as with the monthly trainings held for the Global 
Health Track of the Commission Corps or orientation for new Global Health Fellows.  
STEP 7: SUSTAIN ACCELERATION 
 Building on this momentum, we will ask CDC leadership to formalize the ad hoc GF working 
group, which will increase its credibility and influence. The group will then define its leadership and 
concretize its priorities for the year, which may include pushing for CCM representation, advocating for 
more GF Liaisons, including multilateral issues in CDC training modules, or standardizing strategic 
technical assistance objectives. The goal will be to sustain the visibility of the group’s work and engage 
even more countries and partners in these efforts, bringing in fresh ideas and innovations. The direction of 
the group may be affected by CDC and GF leadership announcements and plans but it should seek to 
address the pressing, persistent issues identified in this research, rather than be fully swept into new 
initiatives or side projects.  
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STEP 8: INSTITUTE CHANGE 
 The issuing of official CDC guidance or development of a strategy on GF engagement and 
implementation by HQ and field staff is the ultimate goal of this work. In order for the priority 
recommendations listed earlier to be fully realized, they must be formally, publicly endorsed by 
leadership and adopted by CDC at all levels. The release of such guidance or strategy may be 
accompanied by new hiring or reassignments, changes in position descriptions for all staff (to ensure a GF 
or partnership component), revised training curricula, and negotiations with GF HQ and other agencies on 
CDC representation on GF structures. Colleagues who have been working on these issues as part of the 
ad hoc group may be called upon to draft this guidance or strategy and assist with dissemination and 
adoption.  
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CHAPTER 6: CONCLUSION 
PUBLIC HEALTH BENEFITS OF THIS RESEARCH 
 This research supports CDC country and HQ teams to identify best practices, challenges, 
bottlenecks, and opportunities for improvement related to engagement with GF. The assessment also 
provides insight into the status of CDC’s current engagement, knowledge levels of GF, expectations for 
in-country USG coordination, and staffing to maximize the impact of GF planning and implementation. If 
implemented, the recommendations here will improve the efficiency and impact of both CDC and GF’s 
work to combat HIV/AIDS, TB, and malaria, as well as to strengthen health systems around the world. In 
a period of flat or declining resources, increasing cost-effectiveness and reducing duplication is critical 
and will stretch funding so it can reach more individuals in need. Continuing the status quo will slow 
progress towards attainment of disease elimination goals, both nationally and globally. Even modest 
changes in how donors interact and collaborate can increase geographic coverage and access to services, 
leading in turn to significant public health impact.  
DRAWBACKS AND LIMITATIONS  
 As stated earlier, this study only includes data from one side of the CDC— GF relationship; this 
prevents a true understanding and exploration of the dynamic between the two institutions. However, 
given the paucity of published information on these groups’ interactions and the challenge of getting full 
access to GF staff for interviews, this study represents a tremendous stride forward in terms of 
documentation and analysis of donor coordination.  
 Another limitation of my research is that I utilized data from a 2015 quantitative survey and 
2017/2018 qualitative interviews. Much has changed since 2015 in the global health landscape and in 
CDC and GF operations, including new leadership at both organizations. As such, some of the findings 
from the 2015 survey may no longer be as valid or relevant, and certain challenges may be less pressing.  
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Finally, the number of qualitative interviews was relatively low but they did confirm many of the 
findings from the survey, indicating that the structural and institutional issues persist even a few years 
after the initial survey. Taken together, the two methodologies suggest enduring challenges in effective 
collaboration that are not likely to naturally dissipate without intervention.  
PLAN FOR FURTHER DISSEMINATION 
The consolidated findings from this research will be modified and shared by CDC leadership with 
staff charged with developing training, policies, and guidance associated with external engagement. 
Tailored recommendations will be developed for each program area (i.e., HIV, TB, malaria) and 
disseminated within CDC. The material may be utilized by CDC leaders in the field and at HQ to better 
leverage CDC resources and systems vis-à-vis GF. Given the frequent turnover and movement of CDC 
staff, this assessment will also serve as an institutional memory of past and current engagement, as well as 
a source of recommendations for future action.  
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APPENDIX B: QUANTITATIVE SURVEY TOOL 
A. About You 
1. Which best describes your current location and main function? (Select one) 
a. CDC-HQ Leadership 
b. CDC-HQ Technical 
c. CDC Country Office Leadership 
d. CDC Country Office Technical 
e. Other (please specify) 
2. Have you served in another location and/or function? (Select all that apply) 
a. CDC-HQ Leadership 
b. CDC-HQ Technical 
c. CDC Country Office Leadership 
d. CDC Country Office Technical 
e. Other (please specify) 
3. In which country do you currently work? (Please specify) 
4. In which organization/office do you currently work? (Center, drop down with 
divisions) 
a. CGH OD 
b. CGH/DGHT 
c. CGH/DPDM 
d. CGH/DPDM/PMI 
e. CGH/DGHP 
f. NCHHSTP/DTBE 
g. NCHHSTP/DHAP 
h. NCEZID/DGMQ 
i. UNAIDS (CDC Secondee) 
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j. WHO (CDC Secondee) 
k. Global Fund (CDC Secondee)  
l. Other (Please specify) 
5. How many years have you worked for CDC? 
a. Less than one year 
b. 1-3 years 
c. 4-6 years 
d. 7-9 years 
e. 9-12 years 
f. 13+ years 
6. How many years have you been involved in activities related to the Global Fund? 
a. Less than one year 
b. 1-3 years 
c. 4-6 years 
d. 7-9 years 
e. 9-12 years 
f. 13+ years 
7. How would you rate your level of interest in the Global Fund? 
a. Very high 
b. High 
c. Moderate 
d. Low 
e. None 
8. How important is the Global Fund to your work? 
a. Very important 
b. Important 
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c. Somewhat important 
d. Not important 
 
B. Engagement 
1. What types of engagement do you have with the Global Fund? (Select all that apply)  
a. Discussions with Country Coordinating Mechanisms (CCMs)  
b. Voting or alternate member of CCM 
c. Technical assistance to host country in developing or revising a National 
Strategic Plan (for purpose of Concept Note development)  
d. Technical assistance to host country in designing and submitting of Concept 
Notes 
e. Participation in mock Technical Review Panel  
f. Technical assistance to Technical Review Panel review 
g. Coordination for implementation of Global Fund supported programs 
h. Site visits to Global Fund supported sites 
i. Technical assistance for monitoring and evaluation of Global Fund activities 
j. Resolution of Management Actions (aka Conditions Precedent) 
k. Strategic coordination with USG/CDC initiatives 
l. Other (please specify) 
2. On which Global Fund grants do you engage? (Select all that apply) 
a. HIV only 
b. TB only 
c. HIV/TB 
d. Malaria 
e. HSS 
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3. Does your CDC office have a cooperative agreement with any Principal Recipients 
(PRs) or Sub-Recipients (SRs) of the Global Fund in your country? (Select all that 
apply.) 
a. Yes, we have a cooperative agreement(s) with one or more PRs 
b. Yes, we have a cooperative agreement(s) with one or more SRs 
c. No 
d. Other (please specify) 
4. Have you ever contributed to the technical development of a Concept Note for a 
program that did not receive USG funds in your country (i.e., supported development 
of a malaria Concept Note even though CDC only receives PEPFAR funds)? 
(Multiple responses for ‘a’ possible) 
a. Yes, we supported _____, _______, and ______ CNs even though we only 
receive USG funding for _______.  
b. No 
5. Does CDC currently engage with the Country Coordinating Mechanism (CCM) in 
your country/region? (Select all that apply) 
a. Yes, we are a voting member  
1. Please specify title(s) of CDC voting member(s) and alternate(s):  
b. Yes, we are a non-voting member or observer  
1. Please specify title(s) of CDC non-voting member(s) and 
alternate(s):  
c. Yes, we are members of CCM sub-committees 
1. Please specify names of sub-committees  
d. Yes, we provide financial and/or technical support to the Secretariat 
e. No, we do not engage with the CCM 
f. Don’t know 
87 
 
6. Does CDC have a permanent seat or alternate position on the CCM? 
a. Yes, CDC has a permanent seat 
b. Yes, CDC has an alternate seat 
c. No, but the USG has a permanent seat and we alternate with ____ (specify 
agency) 
d. No, but the USG has a permanent seat and we alternate with ____ (specify 
agency) 
e. No 
7. If you provide TA to the development of Concept Notes, which sections do you 
provide input on? (Select all that apply) 
a. Country Context  
b. Funding Landscape, Additionality, and Sustainability 
c. Implementation Arrangements and Risk Assessment  
d. Financial Gap Analysis 
e. Programmatic Gap  
f. Modular Template (Program Framework) 
g. Modular Template (Concept Note) 
h. Modular Template (Summary Budget) 
i. Modular Template (Targets) 
j. Other (please specify) 
8. What level would you consider your engagement in Global Fund Concept Note 
development? 
a. Very Substantial 
b. Substantial 
c. Active but not substantial 
d. Limited 
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e. None 
9. How effective do you think you are at influencing the Global Fund Concept Note 
development?  
a. Very effective 
b. Effective 
c. Somewhat effective 
d. Not effective 
e. Do not know 
10. What are challenges has you have faced in in terms of influencing the technical or 
strategic content of Concept Notes? (Select all that apply) 
a. Excessive influence of external consultants 
b. Excessive influence of CCM leadership 
c. Excessive influence of PRs 
d. Excessive influence of SRs 
e. Excessive influence of other donors 
f. Excessive influence of civil society 
g. Lack of transparency 
h. Length of process 
i. Length of meetings, consultations 
j. Poor quality of external consultants 
k. Document management/control  
l. Unclear communication channels for providing feedback 
m. Lack of interest by Fund Portfolio Management Team 
n. Lack of interest by in-country stakeholders 
o. Lack of or poor leadership/organization by host country government 
p. Other (please specify) 
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11. How would you rate the overall quality of work produced by external consultants 
brought in to develop Concept Notes? 
a. Very good 
b. Good 
c. Average 
d. Poor 
e. Very Poor 
f. Don’t know 
12. During the Concept Note development process, approximately how many people on 
the CDC team participate, at what level of effort, and for how long? 
______ people at average ____% level of effort for an average of ____ months 
13. On what topics/activities do you think CDC should provide technical assistance to 
the Global Fund? (Select all that apply) 
a. Epidemiologic analysis and target-setting 
b. Disease-specific programs/interventions 
c. Gaps analysis 
d. Strategic planning 
e. Program planning 
f. Financial analysis and budgeting 
g. Proposal development 
h. Program implementation  
i. Program monitoring and evaluations 
j. Other (please specify) 
14. How do you think CDC should provide TA to the Global Fund, if additional 
resources were available? (Please rank) 
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a. Via CDC in-country technical staff seconded to the Principal Recipient (such 
as the Ministry of Health) or CCM 
b. Via CDC in-country technical staff based in the CDC office 
c. Via CDC HQ technical staff 
d. Via multilateral institutions (e.g., WHO, UNAIDS) 
e. Via a cooperative agreement with an NGO 
f. Other 
15. Apart from the Concept Note development process, how much time do you spend on 
Global Fund activities? 
a. More than 50% 
b. 25%-50% 
c. 5%-25% 
d. 0%-5% 
16. How often do CDC country offices reach out to you with questions and/or updates on 
Global Fund issues in their country? 
a. Very often (at least once per month) 
b. Somewhat often (once every 2-3 months) 
c. Rarely (once or twice a year) 
d. Never 
17. How often does do you reach out to CDC-HQ with questions and/or updates on 
Global Fund issues in your country? 
a. Very often (at least once per month) 
b. Somewhat often (once every 2-3 months) 
c. Rarely (once or twice a year) 
d. Never 
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18. Do you have an official point of contact at CDC-HQ for any questions and/or updates 
you have on Global Fund issues in country?  
a. Yes, we have an official point of contact 
b. No, but we have someone we reach out to unofficially 
c. No, and we do not reach out to anyone unofficially  
19. How many mock Technical Review Panels have you participated in? 
a. 5+ 
b. 3-4 
c. 1-2 
d. 0 
20. Do you have any best practices or recommendations to share regarding CDC 
engagement in Global Fund processes?  
21. In your opinion, what is the most critical action for CDC to take to improve its 
engagement with and technical assistance to the Global Fund?  
 
 
C. Staffing and Knowledge  
1. Does your office have any CDC staff who are dedicated full time to Global Fund 
activities?  
a. Yes (please specify title) 
b. No 
2. Do other agencies in country have staff who are dedicated full time to Global Fund 
activities? 
a. Yes, Department of State 
1. Specify funding source:  
b. Yes, USAID 
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1. Specify funding source:  
c. Other (please specify agency and funding source) 
d. No 
e. Don’t know 
3. Does your country have a lead agency that serves as the primary focal point for 
Global Fund?  
a. Yes, CDC 
b. Yes, USAID 
c. Yes, State 
d. Yes, DOD 
e. No  
4. If you answered B or C above, please describe any coordination the other agency 
does with CDC to get input and feedback on Global Fund activities.  
5. Are you aware of the ongoing Global Fund Strategic Review? 
a. Yes 
b. Yes, but only vaguely 
c. No 
6. Has your CDC office been asked to provide feedback to the Global Fund Strategic 
Review? 
a. Yes, and we met with the consultants in person 
b. Yes, and we provided oral feedback over the phone 
c. Yes, and we provided written feedback via email 
d. Yes, but we have not yet responded 
e. No, we have not been asked 
7. Have you ever received any formal training or briefing on Global Fund processes? 
(Select all that apply) 
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a. Yes, provided by CDC-HQ 
b. Yes, provided by a CDC Country Office 
c. Yes, provided by the Global Fund 
d. Yes, provided by USAID or Department of State 
e. Yes, provided by an external organization 
f. No 
8. Please rate your knowledge of the following Global Fund approaches and processes 
(1 – 5 with 1 being low and 5 being excellent): 
a. Strategy and objectives = __ 
b. CN development = __ 
c. Grant making = __ 
d. Decision making = __ 
e. Implementation = __ 
f. Governance = __ 
g. Monitoring and evaluation standards = __ 
h. Other 
9. How interested are you in learning more about the following (1 – 5 with 1 being not 
interested and 5 being extremely interested):  
a. Strategy and objectives = __ 
b. CN development = __ 
c. Grant making = __ 
d. Decision making = __ 
e. Implementation = __ 
f. Governance = __ 
g. Monitoring and evaluation standards = __ 
h. Other 
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10. How do you currently receive updates about Global Fund policy, strategy, or 
processes? (Select all that apply) 
a. Email or call from Fund Portfolio Manager or other Global Fund staff 
b. Global Fund Observer 
c. Global Fund News Flash 
d. Email, call, or newsletter from CDC HQ  
e. Other (please specify) 
f. I do not currently receive updates  
11. Do you have any best practices or recommendations to share regarding CDC staffing 
to support the Global Fund?  
12. In your opinion, what is the most critical action for CDC to take to improve the 
structures, knowledge, and skills of its teams, as they pertain to the Global Fund?  
 
D. Communication and Coordination  
1. Are your host country’s financial institutions (e.g., Ministry of Finance, Ministry of 
Planning, Ministry of Treasury) active in the Global Fund process? (Select all that 
apply) 
a. Yes, they participate in the Concept Note development process 
b. Yes, they serve as a PR or SR of a Global Fund grant  
c. Yes, they participate in financial monitoring and reporting for Global Fund 
grants 
d. Yes, other (please specify) 
e. No, they do not participate in Global Fund activities 
2. How involved are the following stakeholders in Global Fund activities (1 – 5 with 1 
being not involved and 5 being extremely involved)? 
a. Ministry of Health 
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b. US Embassy Front Office 
c. USAID 
d. WHO/PAHO 
e. UNAIDS 
f. UNICEF 
g. Other UN 
h. CHAI 
i. RBM 
j. Other bilaterals 
k. Other (please specify) 
3. How would you rate the quality of technical or strategic contributions from the 
following stakeholders to Global Fund activities (1 – 5 with 1 being very poor and 5 
being very good)? 
a. Ministry of Health 
b. USAID 
c. WHO/PAHO 
d. UNAIDS 
e. UNICEF 
f. Other UN 
g. Roll Back Malaria 
h. KNCV 
i. Other NGOs 
j. Other bilaterals 
k. Other (please specify) 
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4. How would you rate the quality of technical or strategic contributions from the 
following stakeholders to Global Fund activities (1 – 5 with 1 being very poor and 5 
being very good)? 
a. Ministry of Health 
b. USAID 
c. WHO/PAHO 
d. UNAIDS 
e. UNICEF 
f. Other UN 
g. Roll Back Malaria 
h. KNCV 
i. Other NGOs 
j. Other bilaterals 
k. Other (please specify) 
5. Right now, how frequently does your CDC office have a phone call with the Fund 
Portfolio Manager for your country/countries? 
a. Weekly or every other week 
b. Monthly 
c. Every other month 
d. On an ad hoc basis 
e. Never 
6. Right now, how frequently does your CDC office meet in person with the Fund 
Portfolio Manager for your country? 
a. Weekly or every other week 
b. Monthly 
c. Every other month 
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d. On an ad hoc basis 
e. Never 
7. What are challenges have you faced in in terms of communicating with the Fund 
Portfolio Management Team (FPMT)? (Select all that apply) 
a. CDC not included in USG communication with the FPMT 
b. FPMT does not visit country 
c. Turnover within the FPMT 
d. Lack of interest from the FPMT 
e. Lack of time for calls/emails with FPMT 
f. Differences in technical priorities between CDC and FPMT 
g. Differences in policy or strategic priorities between CDC and FPMT 
h. No point of contact to initiate communication  
i. Other (please specify) 
8. Have or will representatives from organizations involved with the Global Fund 
be participating in person in your regional COP review? (Select all that apply) 
a. Yes, representatives from the FPMT have/will participated 
b. Yes, representatives from the CCM have/will participate 
c. Yes, representatives from the PRs or SRs have/will participate 
d. No  
e. Other (please specify) 
9. How frequently do you proactively share information with the Fund Portfolio 
Management Team? (Frequently, Sometimes, Rarely, Never) 
a. Official plans once cleared 
b. Official plans in draft form 
c. Updates on program implementation 
d. Unofficial updates on the functioning of the CCM, PRs, or SRs 
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e. Other unofficial news, country context 
10. Do you have any best practices or recommendations to share regarding CDC 
communication with other stakeholders on the Global Fund? 
11. In your opinion, what is the most critical action for CDC to take to improve 
communication and coordination with the Global Fund?  
 
 
 
99 
 
APPENDIX C: KEY INFORMANT INTERVIEW QUESTIONAIRE 
1. Please tell me about yourself. What have your roles at CDC been?  
2. How interested are you in engaging with the Global Fund? 
3. What do you see as CDC’s role re the Global Fund? 
4. How did you first start engaging with the Global Fund? What was your role? What did you learn 
from that experience? How effective do you think you were at achieving your or CDC’s goals? 
5. How do you currently engage with the Global Fund? What is your role? In what activities do you 
participate? How effective do you think you are at achieving your or CDC’s goals? 
6. How did you come to learn about the Global Fund’s processes and systems? Did you receive 
training?  
7. What kind of support have you received from CDC HQ to help you engage with the Global 
Fund? (OR: What kind of support do you provide to countries regarding the Global Fund?) 
8. Are there approaches or actions you think help CDC engage more effectively with the Global 
Fund? 
9. What advice would you give to new CDC staff who have been tasked with working with the 
Global Fund? 
10. How do you think CDC should support the Global Fund moving forward? What would you 
change in terms of our support?  
 
  
100 
 
REFERENCES 
The Global Fund, (2018). Allocation Process. [online] Available at: 
http://www.theglobalfund.org/en/fundingmodel/allocationprocess/ [Accessed 4 Apr. 2018]. 
The Global Fund, (2018). Country Coordinating Mechanism. [online] Available at: 
http://www.theglobalfund.org/en/ccm/data/ [Accessed 4 Apr. 2018]. 
The Global Fund, (2018). Financials. [online] Available at: https://www.theglobalfund.org/en/financials/ 
[Accessed 4 Apr. 2018]. 
The Global Fund, (2018). Funding Model. [online] Available at: 
https://www.theglobalfund.org/media/5642/fundingmodel_allocations2017-
2019detailedexplanation_report_en.pdf [Accessed 4 Apr. 2018]. 
The Global Fund, (2018). Global Fund Overview. [online] Available at: 
https://www.theglobalfund.org/en/overview [Accessed 4 Apr. 2018]. 
The Global Fund, (2018). Grant Overview. [online] Available at: 
http://portfolio.theglobalfund.org/en/Home/Index [Accessed 4 Apr. 2018]. 
Healthdata.org. (2018). Financing Global Health | Institute for Health Metrics and Evaluation. [online] 
Available at: http://www.healthdata.org/data-visualization/financing-global-health [Accessed 4 Apr. 
2018]. 
The Henry J. Kaiser Family Foundation. (2018). Budget Tracker. [online] Available at: 
https://www.kff.org/interactive/budget-tracker/landing/ [Accessed 4 Apr. 2018]. 
President’s Emergency Plan for AIDS Relief, (2018). PEPFAR Funding. [online] Available at: 
https://www.pepfar.gov/documents/organization/252516.pdf [Accessed 4 Apr. 2018]. 
President’s Emergency Plan for AIDS Relief, (2018). PEPFAR Bilateral Countries. [online] Available at: 
http://www.pepfar.gov/countries/bilateral/index.htm [Accessed 4 Apr. 2018]. 
President’s Malaria Initiative, (2018). About | PMI. [online] Available at: http://www.pmi.gov/about 
[Accessed 4 Apr. 2018]. 
President’s Malaria Initiative, (2018). Where We Work | PMI. [online] Available at: 
http://www.pmi.gov/where-we-work [Accessed 4 Apr. 2018]. 
U.S. Centers for Disease Control and Prevention, (2018). FY 2015 | Operating Plans | Budget | CDC. 
[online] Available at: https://www.cdc.gov/budget/fy2015/operating-plans.html [Accessed 4 Apr. 
2018]. 
U.S. Centers for Disease Control and Prevention, (2018). Global Health Strategy.[online] Available at: 
https://www.cdc.gov/globalhealth/strategy/pdf/CDC-GlobalHealthStrategy.pdf [Accessed 4 Apr. 
2018]. 
U.S. Centers for Disease Control and Prevention, (2018). Tuberculosis (TB) | CDC. [online] Available at: 
http://www.cdc.gov/tb/topic/globaltb/work.htm [Accessed 4 Apr. 2018]. 
UNAIDS. (2018). AIDSinfo | UNAIDS. [online] Available at: http://aidsinfo.unaids.org/ [Accessed 4 Apr. 
2018]. 
101 
 
World Health Organization, (2018). Global TB. [online] Available at: 
http://www.who.int/gho/tb/epidemic/tb_001.jpg?ua=1 [Accessed 4 Apr. 2018]. 
 
